meehie personal page - To The Moon

meehie

meehie

No personal profile

413Follow

3Followers

0Topic

0Badge

2021-08-09

Good

BioNTech says has supplied more than 1 bln COVID-19 vaccine doses so far

2021-08-08

?

India approves J&J COVID-19 vaccine for emergency use

2021-08-05

Good

SPACs Target Emerging Markets as U.S. Competition Mounts

2022-02-05

Tks sharing

Sorry, the original content has been removed

2021-07-31

Like

You can beat stock market indexes — this fund manager has, and this is how she and her team did it

2021-07-26

Wow

EV stocks surged in Monday morning trading

2022-05-05

Tks sharing

PureTech Health to Buy Back Up to $50 Mln in Shares

2021-07-26

Wow

EV stocks surged in Monday morning trading

08-09

$Straits Times Index(STI.SI)$

2021-06-21

Good

Huawei quietly powers up chipmaking investments

2021-06-21

Good

Huawei quietly powers up chipmaking investments

2021-07-14

Thanks for sharing

Why the CDC and FDA Just Slapped Down Pfizer and Moderna

2021-07-06

Good sharing....

Sorry, the original content has been removed

2021-07-04

Wah

U.S. stocks sweep to fresh highs after strong jobs report

2021-07-01

Good!!

Sorry, the original content has been removed

2021-06-25

Good

Sorry, the original content has been removed

2021-07-01

Good

Sorry, the original content has been removed

2021-07-01

Good

Sorry, the original content has been removed

2021-07-01

Good

CCIV Stock: 5 Reasons Churchill Shares Are Climbing Ahead of a Lucid Motors Merger

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3581503098068541","uuid":"3581503098068541","gmtCreate":1618895187810,"gmtModify":1628933805058,"name":"meehie","pinyin":"meehie","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":413,"tweetSize":23,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.24%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.30","exceedPercentage":"60.22%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":336586275557384,"gmtCreate":1723210545798,"gmtModify":1723370388983,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/STI.SI\">$Straits Times Index(STI.SI)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/STI.SI\">$Straits Times Index(STI.SI)$&nbsp;</a>&nbsp;","text":"$Straits Times Index(STI.SI)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/336586275557384","isVote":1,"tweetType":1,"viewCount":233,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9068159878,"gmtCreate":1651739869494,"gmtModify":1676534959677,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Tks sharing","listText":"Tks sharing","text":"Tks sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9068159878","repostId":"2233950862","repostType":4,"repost":{"id":"2233950862","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1651739300,"share":"https://ttm.financial/m/news/2233950862?lang=&edition=fundamental","pubTime":"2022-05-05 16:28","market":"us","language":"en","title":"PureTech Health to Buy Back Up to $50 Mln in Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2233950862","media":"Dow Jones","summary":"PureTech Health PLC said Thursday that it will launch a share-buyback program of up to $50 million, ","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/PRTC\">PureTech Health PLC</a> said Thursday that it will launch a share-buyback program of up to $50 million, or 28.6 million ordinary shares.</p><p>The clinical-stage biotechnology company said it is confident that it can return the capital to shareholders while continuing to develop and expand its pipeline and strategic investments.</p><p>The company said the buyback program will be executed via open market purchases.</p><p>PureTech had $413.2 million of consolidated cash and cash equivalents as of March 31, it said.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PureTech Health to Buy Back Up to $50 Mln in Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPureTech Health to Buy Back Up to $50 Mln in Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-05-05 16:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/PRTC\">PureTech Health PLC</a> said Thursday that it will launch a share-buyback program of up to $50 million, or 28.6 million ordinary shares.</p><p>The clinical-stage biotechnology company said it is confident that it can return the capital to shareholders while continuing to develop and expand its pipeline and strategic investments.</p><p>The company said the buyback program will be executed via open market purchases.</p><p>PureTech had $413.2 million of consolidated cash and cash equivalents as of March 31, it said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PRTC":"PureTech Health PLC"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2233950862","content_text":"PureTech Health PLC said Thursday that it will launch a share-buyback program of up to $50 million, or 28.6 million ordinary shares.The clinical-stage biotechnology company said it is confident that it can return the capital to shareholders while continuing to develop and expand its pipeline and strategic investments.The company said the buyback program will be executed via open market purchases.PureTech had $413.2 million of consolidated cash and cash equivalents as of March 31, it said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":418,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9098166768,"gmtCreate":1644048091408,"gmtModify":1676533886340,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Tks sharing","listText":"Tks sharing","text":"Tks sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098166768","repostId":"2209341821","repostType":4,"isVote":1,"tweetType":1,"viewCount":659,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898580477,"gmtCreate":1628510353099,"gmtModify":1703507281286,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":13,"repostSize":0,"link":"https://ttm.financial/post/898580477","repostId":"2158844506","repostType":4,"repost":{"id":"2158844506","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1628508062,"share":"https://ttm.financial/m/news/2158844506?lang=&edition=fundamental","pubTime":"2021-08-09 19:21","market":"us","language":"en","title":"BioNTech says has supplied more than 1 bln COVID-19 vaccine doses so far","url":"https://stock-news.laohu8.com/highlight/detail?id=2158844506","media":"Reuters","summary":"FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than one billion doses o","content":"<p>FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca , the German biotech group said on Monday.</p>\n<p>AstraZeneca said on July 29 that it and its manufacturing partner, India-based Serum Institute, had supplied a billion doses to 170 countries at the time.</p>\n<p>Based on delivery contracts so far, BioNTech said in a statement it expects 15.9 billion euros ($18.7 billion) in revenue accruing to it from the vaccine this year, up from a forecast in May of 12.4 billion euros.</p>\n<p>That includes sales, milestone payments from partners and a share of gross profit in its partners' territories, the company added. ($1 = 0.8509 euros)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech says has supplied more than 1 bln COVID-19 vaccine doses so far</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech says has supplied more than 1 bln COVID-19 vaccine doses so far\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-09 19:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca , the German biotech group said on Monday.</p>\n<p>AstraZeneca said on July 29 that it and its manufacturing partner, India-based Serum Institute, had supplied a billion doses to 170 countries at the time.</p>\n<p>Based on delivery contracts so far, BioNTech said in a statement it expects 15.9 billion euros ($18.7 billion) in revenue accruing to it from the vaccine this year, up from a forecast in May of 12.4 billion euros.</p>\n<p>That includes sales, milestone payments from partners and a share of gross profit in its partners' territories, the company added. ($1 = 0.8509 euros)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158844506","content_text":"FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than one billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca , the German biotech group said on Monday.\nAstraZeneca said on July 29 that it and its manufacturing partner, India-based Serum Institute, had supplied a billion doses to 170 countries at the time.\nBased on delivery contracts so far, BioNTech said in a statement it expects 15.9 billion euros ($18.7 billion) in revenue accruing to it from the vaccine this year, up from a forecast in May of 12.4 billion euros.\nThat includes sales, milestone payments from partners and a share of gross profit in its partners' territories, the company added. ($1 = 0.8509 euros)","news_type":1},"isVote":1,"tweetType":1,"viewCount":1097,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891760413,"gmtCreate":1628430549032,"gmtModify":1703506167813,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":12,"repostSize":0,"link":"https://ttm.financial/post/891760413","repostId":"2157492839","repostType":4,"repost":{"id":"2157492839","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1628324123,"share":"https://ttm.financial/m/news/2157492839?lang=&edition=fundamental","pubTime":"2021-08-07 16:15","market":"us","language":"en","title":"India approves J&J COVID-19 vaccine for emergency use","url":"https://stock-news.laohu8.com/highlight/detail?id=2157492839","media":"Reuters","summary":"Aug 7 (Reuters) - India approved Johnson & Johnson's single-dose COVID-19 vaccine for emergency use ","content":"<p>Aug 7 (Reuters) - India approved Johnson &amp; Johnson's single-dose COVID-19 vaccine for emergency use on Saturday, health minister Mansukh Mandaviya said in a tweet.</p>\n<p>The pharmaceutical giant had applied for emergency use approval on Friday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>India approves J&J COVID-19 vaccine for emergency use</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIndia approves J&J COVID-19 vaccine for emergency use\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-07 16:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Aug 7 (Reuters) - India approved Johnson &amp; Johnson's single-dose COVID-19 vaccine for emergency use on Saturday, health minister Mansukh Mandaviya said in a tweet.</p>\n<p>The pharmaceutical giant had applied for emergency use approval on Friday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2157492839","content_text":"Aug 7 (Reuters) - India approved Johnson & Johnson's single-dose COVID-19 vaccine for emergency use on Saturday, health minister Mansukh Mandaviya said in a tweet.\nThe pharmaceutical giant had applied for emergency use approval on Friday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1144,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899173312,"gmtCreate":1628171444836,"gmtModify":1703502518229,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":12,"repostSize":0,"link":"https://ttm.financial/post/899173312","repostId":"1123028494","repostType":4,"repost":{"id":"1123028494","kind":"news","pubTimestamp":1628168579,"share":"https://ttm.financial/m/news/1123028494?lang=&edition=fundamental","pubTime":"2021-08-05 21:02","market":"us","language":"en","title":"SPACs Target Emerging Markets as U.S. Competition Mounts","url":"https://stock-news.laohu8.com/highlight/detail?id=1123028494","media":"The Wall Street Journal","summary":"The number of blank-check companies focused on developing countries has almost tripled in 2021 as in","content":"<blockquote>\n The number of blank-check companies focused on developing countries has almost tripled in 2021 as investors look for better value overseas.\n</blockquote>\n<p>Blank-check companies are venturing to far-flung locales such as Brazil, Israel and Turkey to find attractive merger targets these days.</p>\n<p>Special-purpose acquisition companies, or SPACs, explicitly pursuing companies in Asia, Latin America, Eastern Europe, the Middle East and Africa remain a small part of the overall market. But they are growing at a faster clip than their conventional counterparts, according to The Wall Street Journal’s analysis of data from SPAC Research.</p>\n<p>Sixty new SPACs focused on emerging markets filed documents with the Securities and Exchange Commission in the first half of 2021, almost triple the number for all of 2020, according to the analysis. The number of non-emerging-market SPACs grew by about 67% to 515 over the same period.</p>\n<p>The surge coincides with mounting competition that has driven up purchase prices, and a selloff that has buffeted the U.S. SPAC market in recent months.</p>\n<p>SPACs are shell firms that raise money on stock exchanges, then merge with private companies and take them public. With so-manybuyers chasing dealsin the U.S., blank-check companies are more likely to overpay or to purchase speculative businesses because they must close deals within two years of launching or give investors their money back. The bidding wars have grown so heated that Wall Street insiders have taken to calling them SPAC-offs.</p>\n<p>“People are finding two Stanford dropouts with a twinkle in their eye and a plan to colonize Venus and giving them $2 billion,” said Daniel Freifeld, founder of Callaway Capital Management LLC, a money manager focused on emerging markets.</p>\n<p>Callaway completed a $125 million SPAC in July that listed on the New York Stock Exchange and is targeting Turkish financial-technology companies.</p>\n<p>Turkey is a prime example of the risks that foreign investors take playing in developing markets. Political instability, high inflation and erratic monetary policy have sent the country’s stock market andcurrency into a tailspindespite the global economic recovery this year. The Turkey BIST 100 stock index lost 5.2% in 2021 through Aug. 2, making it the third-worst performer of the global benchmark indexes listed by FactSet.</p>\n<p>“Nowhere in the world is cheaper than Turkey right now,” Mr. Freifeld said&nbsp;Still, the country’s banks and insurance companies are well capitalized and its young population is underbanked, creating strong growth prospects for the financial sector, according to Mr. Freifeld, who says Turkish assets are unlikely to fall much further.</p>\n<p>Most SPACs focused on emerging markets list on U.S. stock exchanges, where relatively stringent reporting and regulatory requirements give investors comfort, said Matthew Simpson, managing partner at WealthSpring Capital, which has about $750 million it invests in SPACs. They also give SPAC investors a way to reduce concentration in the U.S., where lofty valuations andwarnings from regulatorshave recently sparkeda sharp selloff.</p>\n<p>“We actually like adding a lot of foreign-focused SPACs in our portfolio because it adds diversity,” Mr. Simpson said.</p>\n<p></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SPACs Target Emerging Markets as U.S. Competition Mounts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSPACs Target Emerging Markets as U.S. Competition Mounts\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 21:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/spacs-target-emerging-markets-as-u-s-competition-mounts-11628161381?mod=markets_lead_pos4><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The number of blank-check companies focused on developing countries has almost tripled in 2021 as investors look for better value overseas.\n\nBlank-check companies are venturing to far-flung locales ...</p>\n\n<a href=\"https://www.wsj.com/articles/spacs-target-emerging-markets-as-u-s-competition-mounts-11628161381?mod=markets_lead_pos4\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.wsj.com/articles/spacs-target-emerging-markets-as-u-s-competition-mounts-11628161381?mod=markets_lead_pos4","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123028494","content_text":"The number of blank-check companies focused on developing countries has almost tripled in 2021 as investors look for better value overseas.\n\nBlank-check companies are venturing to far-flung locales such as Brazil, Israel and Turkey to find attractive merger targets these days.\nSpecial-purpose acquisition companies, or SPACs, explicitly pursuing companies in Asia, Latin America, Eastern Europe, the Middle East and Africa remain a small part of the overall market. But they are growing at a faster clip than their conventional counterparts, according to The Wall Street Journal’s analysis of data from SPAC Research.\nSixty new SPACs focused on emerging markets filed documents with the Securities and Exchange Commission in the first half of 2021, almost triple the number for all of 2020, according to the analysis. The number of non-emerging-market SPACs grew by about 67% to 515 over the same period.\nThe surge coincides with mounting competition that has driven up purchase prices, and a selloff that has buffeted the U.S. SPAC market in recent months.\nSPACs are shell firms that raise money on stock exchanges, then merge with private companies and take them public. With so-manybuyers chasing dealsin the U.S., blank-check companies are more likely to overpay or to purchase speculative businesses because they must close deals within two years of launching or give investors their money back. The bidding wars have grown so heated that Wall Street insiders have taken to calling them SPAC-offs.\n“People are finding two Stanford dropouts with a twinkle in their eye and a plan to colonize Venus and giving them $2 billion,” said Daniel Freifeld, founder of Callaway Capital Management LLC, a money manager focused on emerging markets.\nCallaway completed a $125 million SPAC in July that listed on the New York Stock Exchange and is targeting Turkish financial-technology companies.\nTurkey is a prime example of the risks that foreign investors take playing in developing markets. Political instability, high inflation and erratic monetary policy have sent the country’s stock market andcurrency into a tailspindespite the global economic recovery this year. The Turkey BIST 100 stock index lost 5.2% in 2021 through Aug. 2, making it the third-worst performer of the global benchmark indexes listed by FactSet.\n“Nowhere in the world is cheaper than Turkey right now,” Mr. Freifeld said Still, the country’s banks and insurance companies are well capitalized and its young population is underbanked, creating strong growth prospects for the financial sector, according to Mr. Freifeld, who says Turkish assets are unlikely to fall much further.\nMost SPACs focused on emerging markets list on U.S. stock exchanges, where relatively stringent reporting and regulatory requirements give investors comfort, said Matthew Simpson, managing partner at WealthSpring Capital, which has about $750 million it invests in SPACs. They also give SPAC investors a way to reduce concentration in the U.S., where lofty valuations andwarnings from regulatorshave recently sparkeda sharp selloff.\n“We actually like adding a lot of foreign-focused SPACs in our portfolio because it adds diversity,” Mr. Simpson said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1028,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802186750,"gmtCreate":1627733831370,"gmtModify":1703495327500,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":10,"repostSize":0,"link":"https://ttm.financial/post/802186750","repostId":"1147779023","repostType":4,"repost":{"id":"1147779023","kind":"news","pubTimestamp":1627716124,"share":"https://ttm.financial/m/news/1147779023?lang=&edition=fundamental","pubTime":"2021-07-31 15:22","market":"us","language":"en","title":"You can beat stock market indexes — this fund manager has, and this is how she and her team did it","url":"https://stock-news.laohu8.com/highlight/detail?id=1147779023","media":"MarketWatch","summary":"Five key lessons on outperformance from Prabha Ram at the American Century Focused Dynamic Growth Fu","content":"<blockquote>\n <b>Five key lessons on outperformance from Prabha Ram at the American Century Focused Dynamic Growth Fund.</b>\n</blockquote>\n<p>Investing is a tough game. That’s why so many mutual funds lag behind their indices.</p>\n<p>So when you find a fund with a great record, it pays to investigate what the fund managers are doing — to learn some lessons.</p>\n<p>The American Century Focused Dynamic Growth FundACFSXfits the bill. The $2.8 billion fund beats its Russell 1000 Growth&nbsp;Index by over 6 percentage points annualized over the past three and five years, according toMorningstar. It outperforms its large-growth category by 8.6 percentage points annualized over five years. It has a reasonable 0.65% expense ratio.</p>\n<p>The fund is co-managed by Prabha Ram, who I recently caught up with. Raised in India, Ram came to the U.S. as a teaching assistant at the University of Maine, where she earned a master’s degree in computer science. She went on to receive an MBA at the Wharton School at the University of Pennsylvania. Ram and three other portfolio managers have led this fund since 2016.</p>\n<p>Here are the five key takeaways, with examples of specific stocks.</p>\n<p><b>1. Own companies that can “land and expand” in big markets</b></p>\n<p>Even though we’ve been in the digital age for years, many small companies still do much of their business on paper. Bill.comBILLwants to change that. The company was founded by CEO René Lacerte, who in the late 1990s started the online payroll company PayCycle, which was acquired by Intuit.</p>\n<p>Bill.com helps small companies go digital in accounts payable and receivable payments. But that’s just the start. Once inside a company, Bill.com digitizes other areas like cash and expense account management.</p>\n<p>Bill.com “lands and expands” at clients, but it also uses their business partners to create a network of leads.</p>\n<p>“Every vendor is a network member, even if it is not a Bill.com customer,” says Ram. This network has about 2.5 million members. Bill.com also gets prospects from its partners, including Bank of AmericaBAC,JPMorgan ChaseJPMand American ExpressAXP.Sales grew 45% in the first quarter.</p>\n<p>Founder-run companies such as this one are worth considering because they often outperform.</p>\n<p><b>2. Seek out innovators</b></p>\n<p>Ram’s portfolio contains obvious innovators, including TeslaTSLA,Amazon.comAMZNand AlphabetGOOGL,her top three positions. Let’s look beyond technology — to beer.</p>\n<p>Back in the 1980s, Boston Beer founder Jim Koch began taking share from beer giants Anheuser-Busch InBevBUDand HeinekenHEINYby rolling out successful “craft” brews, starting with Samuel Adams. Koch helped invent the craft brew category, essentially taking the country back to pre-Prohibition days when the U.S. had hundreds of regional breweries making more flavorful beers for local tastes.</p>\n<p>Boston Beer stock did very well, but then it stalled during 2015-2017 as beer sales overall went flat. In response, Boston Beer helped put a new category on the map — with its Truly Hard Seltzer brand rolled out in 2106. It remains one of the leading hard seltzers.</p>\n<p>“We were drawn to the company because of its history of innovation,” says Ram, referring to her fund’s early position from the second quarter of 2016. “The stock was doing poorly because the beer market was flattening, but they were coming up with Truly Hard Seltzer. Truly was more successful than we anticipated. It created a new category.”</p>\n<p>This penchant for innovation at Boston Beer has helped keep Ram’s fund in the name. Other successful Boston Beer brands include Twisted Tea, Angry Orchard and Dogfish Head.</p>\n<p>A key takeaway here is that to find innovative companies, look for the ones led by people who have demonstrated a knack for innovation in the past. Innovative managers tend to keep on innovating. Boston Beer continually tests new seltzers, beers, hard ciders, distilled spirits and other drinks. Shareholders are betting they will come through again.</p>\n<p>They’ll need the help. Boston Beer shares fell 20% on July 23 because so many competitors entered the hard cider niche. Sales grew 33% but net income fell 1.6% as the company jacked up advertising costs to try to combat the competition. The company slashed estimates for the year on an expected slowdown in sales growth.</p>\n<p>But don’t count out this innovator yet.</p>\n<p>“We recently announced plans to develop new innovative beverages with&nbsp;Beam Suntory&nbsp;that we are planning to launch in early 2022,” Boston Beer’s Koch said. Beam Suntory&nbsp;sells Jim Beam whiskey and other brands of spirits. “We believe these new beverages will further demonstrate our ability to innovate and grow our business as drinker preferences evolve.”</p>\n<p><b>3. Look for companies that can create and dominate a niche</b></p>\n<p>For years as the gig economy emerged, the big credit card companies didn’t really care that much if the local yoga instructor could accept payments with a credit card. SquareSQrecognized this as an opportunity. So it launched its card payment device business in 2009. Since then, it has grown by taking on larger customers, and expanding into new lines of business in financial services such as cash management, debit cards loans and tax filing. Transaction-based revenue grew 27% in the first quarter, and subscription and services revenue soared 88%.</p>\n<p>This is a great example of a company that created a business niche. But it’s also a “land and expand” company because it grows by offering customers new services. Both qualities help companies maintain the competitive advantage Ram likes see in investments.</p>\n<p><b>4. Buy companies in the early stages of rapid growth</b></p>\n<p>One way to find these is to identify companies developing products that will transform an entire industry. Ram thinks that is the case with Alnylam PharmaceuticalsALNY.It’s developing novel therapies base on a technique called RNA interference (RNAi). Inside the body, messenger RNA (mRNA) encodes proteins we need, based on signals from RNA. Sometimes mRNA gets the signals crossed, and it encodes flawed proteins. This causes diseases.</p>\n<p>Alnylam has developed a way to tweak the RNAi pathway to silence the flawed signaling and block the creation of disease-causing proteins. So far, Alnylam has four approved RNAi-based medicines that treat rare hereditary diseases. The company has a dozen other therapies in clinical studies, including six in late-stage development.</p>\n<p>“This is a completely new area of therapeutics,” says Ram. “It is a platform of products that can treat a variety of conditions.”</p>\n<p><b>5. Hold stocks for the long term</b></p>\n<p>All of the names above are large positions in Ram’s fund, which tells me that Ram and her team think they have considerably more upside. If you buy any of them, though, remember you have to do so with a multi-year time horizon. That’s what Ram’s fund does. It has a low annual portfolio turnover of 27%. It’s important to have a long-term view, because it is so tough to call short-term moves in the stock market or in stocks, and you need to give companies time to develop.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>You can beat stock market indexes — this fund manager has, and this is how she and her team did it</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYou can beat stock market indexes — this fund manager has, and this is how she and her team did it\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-31 15:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/you-can-beat-stock-market-indexes-this-fund-manager-has-and-this-is-how-she-and-her-team-did-it-11627481445?mod=article_inline><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Five key lessons on outperformance from Prabha Ram at the American Century Focused Dynamic Growth Fund.\n\nInvesting is a tough game. That’s why so many mutual funds lag behind their indices.\nSo when ...</p>\n\n<a href=\"https://www.marketwatch.com/story/you-can-beat-stock-market-indexes-this-fund-manager-has-and-this-is-how-she-and-her-team-did-it-11627481445?mod=article_inline\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯","SPY":"标普500ETF",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://www.marketwatch.com/story/you-can-beat-stock-market-indexes-this-fund-manager-has-and-this-is-how-she-and-her-team-did-it-11627481445?mod=article_inline","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147779023","content_text":"Five key lessons on outperformance from Prabha Ram at the American Century Focused Dynamic Growth Fund.\n\nInvesting is a tough game. That’s why so many mutual funds lag behind their indices.\nSo when you find a fund with a great record, it pays to investigate what the fund managers are doing — to learn some lessons.\nThe American Century Focused Dynamic Growth FundACFSXfits the bill. The $2.8 billion fund beats its Russell 1000 Growth Index by over 6 percentage points annualized over the past three and five years, according toMorningstar. It outperforms its large-growth category by 8.6 percentage points annualized over five years. It has a reasonable 0.65% expense ratio.\nThe fund is co-managed by Prabha Ram, who I recently caught up with. Raised in India, Ram came to the U.S. as a teaching assistant at the University of Maine, where she earned a master’s degree in computer science. She went on to receive an MBA at the Wharton School at the University of Pennsylvania. Ram and three other portfolio managers have led this fund since 2016.\nHere are the five key takeaways, with examples of specific stocks.\n1. Own companies that can “land and expand” in big markets\nEven though we’ve been in the digital age for years, many small companies still do much of their business on paper. Bill.comBILLwants to change that. The company was founded by CEO René Lacerte, who in the late 1990s started the online payroll company PayCycle, which was acquired by Intuit.\nBill.com helps small companies go digital in accounts payable and receivable payments. But that’s just the start. Once inside a company, Bill.com digitizes other areas like cash and expense account management.\nBill.com “lands and expands” at clients, but it also uses their business partners to create a network of leads.\n“Every vendor is a network member, even if it is not a Bill.com customer,” says Ram. This network has about 2.5 million members. Bill.com also gets prospects from its partners, including Bank of AmericaBAC,JPMorgan ChaseJPMand American ExpressAXP.Sales grew 45% in the first quarter.\nFounder-run companies such as this one are worth considering because they often outperform.\n2. Seek out innovators\nRam’s portfolio contains obvious innovators, including TeslaTSLA,Amazon.comAMZNand AlphabetGOOGL,her top three positions. Let’s look beyond technology — to beer.\nBack in the 1980s, Boston Beer founder Jim Koch began taking share from beer giants Anheuser-Busch InBevBUDand HeinekenHEINYby rolling out successful “craft” brews, starting with Samuel Adams. Koch helped invent the craft brew category, essentially taking the country back to pre-Prohibition days when the U.S. had hundreds of regional breweries making more flavorful beers for local tastes.\nBoston Beer stock did very well, but then it stalled during 2015-2017 as beer sales overall went flat. In response, Boston Beer helped put a new category on the map — with its Truly Hard Seltzer brand rolled out in 2106. It remains one of the leading hard seltzers.\n“We were drawn to the company because of its history of innovation,” says Ram, referring to her fund’s early position from the second quarter of 2016. “The stock was doing poorly because the beer market was flattening, but they were coming up with Truly Hard Seltzer. Truly was more successful than we anticipated. It created a new category.”\nThis penchant for innovation at Boston Beer has helped keep Ram’s fund in the name. Other successful Boston Beer brands include Twisted Tea, Angry Orchard and Dogfish Head.\nA key takeaway here is that to find innovative companies, look for the ones led by people who have demonstrated a knack for innovation in the past. Innovative managers tend to keep on innovating. Boston Beer continually tests new seltzers, beers, hard ciders, distilled spirits and other drinks. Shareholders are betting they will come through again.\nThey’ll need the help. Boston Beer shares fell 20% on July 23 because so many competitors entered the hard cider niche. Sales grew 33% but net income fell 1.6% as the company jacked up advertising costs to try to combat the competition. The company slashed estimates for the year on an expected slowdown in sales growth.\nBut don’t count out this innovator yet.\n“We recently announced plans to develop new innovative beverages with Beam Suntory that we are planning to launch in early 2022,” Boston Beer’s Koch said. Beam Suntory sells Jim Beam whiskey and other brands of spirits. “We believe these new beverages will further demonstrate our ability to innovate and grow our business as drinker preferences evolve.”\n3. Look for companies that can create and dominate a niche\nFor years as the gig economy emerged, the big credit card companies didn’t really care that much if the local yoga instructor could accept payments with a credit card. SquareSQrecognized this as an opportunity. So it launched its card payment device business in 2009. Since then, it has grown by taking on larger customers, and expanding into new lines of business in financial services such as cash management, debit cards loans and tax filing. Transaction-based revenue grew 27% in the first quarter, and subscription and services revenue soared 88%.\nThis is a great example of a company that created a business niche. But it’s also a “land and expand” company because it grows by offering customers new services. Both qualities help companies maintain the competitive advantage Ram likes see in investments.\n4. Buy companies in the early stages of rapid growth\nOne way to find these is to identify companies developing products that will transform an entire industry. Ram thinks that is the case with Alnylam PharmaceuticalsALNY.It’s developing novel therapies base on a technique called RNA interference (RNAi). Inside the body, messenger RNA (mRNA) encodes proteins we need, based on signals from RNA. Sometimes mRNA gets the signals crossed, and it encodes flawed proteins. This causes diseases.\nAlnylam has developed a way to tweak the RNAi pathway to silence the flawed signaling and block the creation of disease-causing proteins. So far, Alnylam has four approved RNAi-based medicines that treat rare hereditary diseases. The company has a dozen other therapies in clinical studies, including six in late-stage development.\n“This is a completely new area of therapeutics,” says Ram. “It is a platform of products that can treat a variety of conditions.”\n5. Hold stocks for the long term\nAll of the names above are large positions in Ram’s fund, which tells me that Ram and her team think they have considerably more upside. If you buy any of them, though, remember you have to do so with a multi-year time horizon. That’s what Ram’s fund does. It has a low annual portfolio turnover of 27%. It’s important to have a long-term view, because it is so tough to call short-term moves in the stock market or in stocks, and you need to give companies time to develop.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1194,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":800544481,"gmtCreate":1627309952343,"gmtModify":1703487389201,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":9,"repostSize":0,"link":"https://ttm.financial/post/800544481","repostId":"1150818931","repostType":4,"repost":{"id":"1150818931","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627309255,"share":"https://ttm.financial/m/news/1150818931?lang=&edition=fundamental","pubTime":"2021-07-26 22:20","market":"us","language":"en","title":"EV stocks surged in Monday morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1150818931","media":"Tiger Newspress","summary":"EV stocks surged in Monday morning trading.Lucid Motors spikes 12%,Xpeng Motors and Li Auto jumped 4","content":"<p>EV stocks surged in Monday morning trading.Lucid Motors spikes&nbsp;12%,Xpeng Motors and Li Auto&nbsp;jumped&nbsp;4%,Tesla&nbsp;and&nbsp;Nio&nbsp;rose&nbsp;2%.</p>\n<p><img src=\"https://static.tigerbbs.com/68b40eae8375c009ccfbb5d7183d05ce\" tg-width=\"354\" tg-height=\"476\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks surged in Monday morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks surged in Monday morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-26 22:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EV stocks surged in Monday morning trading.Lucid Motors spikes&nbsp;12%,Xpeng Motors and Li Auto&nbsp;jumped&nbsp;4%,Tesla&nbsp;and&nbsp;Nio&nbsp;rose&nbsp;2%.</p>\n<p><img src=\"https://static.tigerbbs.com/68b40eae8375c009ccfbb5d7183d05ce\" tg-width=\"354\" tg-height=\"476\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车","FSR":"菲斯克","NIO":"蔚来","LI":"理想汽车","NKLA":"Nikola Corporation","LCID":"Lucid Group Inc","TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150818931","content_text":"EV stocks surged in Monday morning trading.Lucid Motors spikes 12%,Xpeng Motors and Li Auto jumped 4%,Tesla and Nio rose 2%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":843,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":800544900,"gmtCreate":1627309934300,"gmtModify":1703487388053,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":9,"repostSize":0,"link":"https://ttm.financial/post/800544900","repostId":"1150818931","repostType":4,"repost":{"id":"1150818931","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627309255,"share":"https://ttm.financial/m/news/1150818931?lang=&edition=fundamental","pubTime":"2021-07-26 22:20","market":"us","language":"en","title":"EV stocks surged in Monday morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1150818931","media":"Tiger Newspress","summary":"EV stocks surged in Monday morning trading.Lucid Motors spikes 12%,Xpeng Motors and Li Auto jumped 4","content":"<p>EV stocks surged in Monday morning trading.Lucid Motors spikes&nbsp;12%,Xpeng Motors and Li Auto&nbsp;jumped&nbsp;4%,Tesla&nbsp;and&nbsp;Nio&nbsp;rose&nbsp;2%.</p>\n<p><img src=\"https://static.tigerbbs.com/68b40eae8375c009ccfbb5d7183d05ce\" tg-width=\"354\" tg-height=\"476\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks surged in Monday morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks surged in Monday morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-26 22:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EV stocks surged in Monday morning trading.Lucid Motors spikes&nbsp;12%,Xpeng Motors and Li Auto&nbsp;jumped&nbsp;4%,Tesla&nbsp;and&nbsp;Nio&nbsp;rose&nbsp;2%.</p>\n<p><img src=\"https://static.tigerbbs.com/68b40eae8375c009ccfbb5d7183d05ce\" tg-width=\"354\" tg-height=\"476\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车","FSR":"菲斯克","NIO":"蔚来","LI":"理想汽车","NKLA":"Nikola Corporation","LCID":"Lucid Group Inc","TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150818931","content_text":"EV stocks surged in Monday morning trading.Lucid Motors spikes 12%,Xpeng Motors and Li Auto jumped 4%,Tesla and Nio rose 2%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1062,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":145454267,"gmtCreate":1626240569059,"gmtModify":1703756163447,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Thanks for sharing&nbsp;","listText":"Thanks for sharing&nbsp;","text":"Thanks for sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/145454267","repostId":"2151550481","repostType":4,"repost":{"id":"2151550481","kind":"highlight","pubTimestamp":1626231600,"share":"https://ttm.financial/m/news/2151550481?lang=&edition=fundamental","pubTime":"2021-07-14 11:00","market":"us","language":"en","title":"Why the CDC and FDA Just Slapped Down Pfizer and Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2151550481","media":"Motley Fool","summary":"There's a bit of a brouhaha over booster doses.","content":"<p><b>Pfizer</b> (NYSE:PFE)&nbsp;and&nbsp;<b>Moderna</b> (NASDAQ:MRNA) have enjoyed good working relationships with both the Centers for Disease Control &amp; Prevention (CDC) and the U.S. Food and Drug Administration (FDA). The FDA granted quick approvals to both drugmakers' COVID-19 vaccines last December. The CDC has encouraged Americans to receive both vaccines.</p>\n<p>However, some might now think that the honeymoon is over. Pfizer and Moderna have recently expressed support for booster doses. The CDC and FDA issued a joint public statement last week that appeared to contradict this view. Here's why the two federal agencies just slapped down Pfizer and Moderna.</p>\n<p><img src=\"https://static.tigerbbs.com/9282ceea65d6d87d5e9d88017233aa2a\" tg-width=\"700\" tg-height=\"408\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>A quick and forceful response</h3>\n<p>On July 8, Pfizer chief scientific officer Mikael Dolsten told Reuters in an interview that his company and its partner, <b>BioNTech</b> (NASDAQ:BNTX), plan to soon file for U.S. and European emergency use authorizations (EUA) for a third booster dose. In a separate interview on the same day with CTV News Channel, Moderna co-founder Derrick Rossi said that \"a booster is almost certainly the way.\"</p>\n<p>Rossi doesn't serve on Moderna's management team or board of directors,&nbsp;so his comments didn't represent the biotech's official stance. However, Moderna CEO Stephane Bancel stated in the company's first-quarter conference call: \"We have said for right now that we believe booster shots will be needed as we believe that the virus is not going away.\"</p>\n<p>Later in the day on July 8, the CDC and FDA issued a joint statement on vaccine boosters. The agencies stated:</p>\n<blockquote>\n Americans who have been fully vaccinated do not need a booster shot at this time. FDA, CDC, and NIH are engaged in a science-based, rigorous process to consider whether or when a booster might be necessary. This process takes into account laboratory data, clinical trial data, and cohort data -- which can include data from specific pharmaceutical companies, but does not rely on those data exclusively. We continue to review any new data as it becomes available and will keep the public informed. We are prepared for booster doses if and when the science demonstrates that they are needed.\n</blockquote>\n<p>The CDC-FDA statement appeared to be a direct slap-down -- especially to Pfizer. But why would the agencies respond so quickly and forcefully? The main reason is probably that they don't want to worry Americans who have already been vaccinated, nor give any reason for unvaccinated individuals to delay receiving a vaccine.</p>\n<p>However, I suspect that the FDA, in particular, also had another motivation. The agency doesn't want to be viewed as having too cozy of a relationship with any drugmaker. It has been heavily criticized for the process followed in approving <b>Biogen</b>'s Alzheimer's disease drug Aduhelm. FDA Commissioner Dr. Janet Woodcock even requested an independent investigation into interactions between the agency's staff and Biogen during the review process for the drug.</p>\n<h3>Reconciliable differences</h3>\n<p>Despite the seeming squabble, I don't think that the CDC and the FDA are really in direct opposition to what Pfizer and Moderna have said. There are several similarities between their public statements.</p>\n<p>Both sides agree that the currently available messenger RNA (mRNA) vaccines remain effective at preventing COVID-19. Both also look to data to form their views.</p>\n<p>Pfizer and BioNTech stated last week that their initial data indicates that a third booster dose generates significantly higher antibody levels than only two doses -- five to 10 times more. The CDC and FDA haven't seen this data yet, though. Pfizer and BioNTech expect to submit the data to the FDA as well as to the European Medicines Agency and other regulatory authorities within the next few weeks.</p>\n<p>The differences between the CDC-FDA view and Pfizer-BioNTech-Moderna perspective appear to be mainly related to timing. The drugmakers believe they've seen enough data to know now that booster doses will be needed, while the federal agencies think they need to see more data but aren't ruling out the potential need for booster doses.</p>\n<h3>Why all of this matters</h3>\n<p>Clearly, Pfizer, BioNTech, and Moderna benefit financially if booster doses are needed. The more COVID-19 vaccine doses are required, the higher the companies' sales will be and the better the vaccine stocks will likely perform.</p>\n<p>Government agencies aren't (or at least shouldn't be) concerned with how much money any of these companies make. However, they are responsible for promoting public health. If booster doses are what it takes to effectively fight the spread of COVID-19, they'll be authorized.</p>\n<p>My hunch is that the recent real-world data from Israel gives a good clue as to what will happen going forward. That data found only 64% efficacy of the Pfizer-BioNTech vaccine against COVID-19 overall, down from 94% a month earlier, primarily because of the spread of the delta variant. If a third booster dose can get efficacy closer to the initial level, it would be shocking if authorizations aren't granted.</p>\n<p>Pfizer, Moderna, the CDC, and the FDA might not always be in harmony. However, I predict they'll soon be singing from the same page when it comes to the need for booster doses.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why the CDC and FDA Just Slapped Down Pfizer and Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy the CDC and FDA Just Slapped Down Pfizer and Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-14 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/13/why-the-fda-and-cdc-just-slapped-down-pfizer-and-m/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) have enjoyed good working relationships with both the Centers for Disease Control & Prevention (CDC) and the U.S. Food and Drug Administration (FDA). The ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/13/why-the-fda-and-cdc-just-slapped-down-pfizer-and-m/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/07/13/why-the-fda-and-cdc-just-slapped-down-pfizer-and-m/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2151550481","content_text":"Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) have enjoyed good working relationships with both the Centers for Disease Control & Prevention (CDC) and the U.S. Food and Drug Administration (FDA). The FDA granted quick approvals to both drugmakers' COVID-19 vaccines last December. The CDC has encouraged Americans to receive both vaccines.\nHowever, some might now think that the honeymoon is over. Pfizer and Moderna have recently expressed support for booster doses. The CDC and FDA issued a joint public statement last week that appeared to contradict this view. Here's why the two federal agencies just slapped down Pfizer and Moderna.\n\nImage source: Getty Images.\nA quick and forceful response\nOn July 8, Pfizer chief scientific officer Mikael Dolsten told Reuters in an interview that his company and its partner, BioNTech (NASDAQ:BNTX), plan to soon file for U.S. and European emergency use authorizations (EUA) for a third booster dose. In a separate interview on the same day with CTV News Channel, Moderna co-founder Derrick Rossi said that \"a booster is almost certainly the way.\"\nRossi doesn't serve on Moderna's management team or board of directors, so his comments didn't represent the biotech's official stance. However, Moderna CEO Stephane Bancel stated in the company's first-quarter conference call: \"We have said for right now that we believe booster shots will be needed as we believe that the virus is not going away.\"\nLater in the day on July 8, the CDC and FDA issued a joint statement on vaccine boosters. The agencies stated:\n\n Americans who have been fully vaccinated do not need a booster shot at this time. FDA, CDC, and NIH are engaged in a science-based, rigorous process to consider whether or when a booster might be necessary. This process takes into account laboratory data, clinical trial data, and cohort data -- which can include data from specific pharmaceutical companies, but does not rely on those data exclusively. We continue to review any new data as it becomes available and will keep the public informed. We are prepared for booster doses if and when the science demonstrates that they are needed.\n\nThe CDC-FDA statement appeared to be a direct slap-down -- especially to Pfizer. But why would the agencies respond so quickly and forcefully? The main reason is probably that they don't want to worry Americans who have already been vaccinated, nor give any reason for unvaccinated individuals to delay receiving a vaccine.\nHowever, I suspect that the FDA, in particular, also had another motivation. The agency doesn't want to be viewed as having too cozy of a relationship with any drugmaker. It has been heavily criticized for the process followed in approving Biogen's Alzheimer's disease drug Aduhelm. FDA Commissioner Dr. Janet Woodcock even requested an independent investigation into interactions between the agency's staff and Biogen during the review process for the drug.\nReconciliable differences\nDespite the seeming squabble, I don't think that the CDC and the FDA are really in direct opposition to what Pfizer and Moderna have said. There are several similarities between their public statements.\nBoth sides agree that the currently available messenger RNA (mRNA) vaccines remain effective at preventing COVID-19. Both also look to data to form their views.\nPfizer and BioNTech stated last week that their initial data indicates that a third booster dose generates significantly higher antibody levels than only two doses -- five to 10 times more. The CDC and FDA haven't seen this data yet, though. Pfizer and BioNTech expect to submit the data to the FDA as well as to the European Medicines Agency and other regulatory authorities within the next few weeks.\nThe differences between the CDC-FDA view and Pfizer-BioNTech-Moderna perspective appear to be mainly related to timing. The drugmakers believe they've seen enough data to know now that booster doses will be needed, while the federal agencies think they need to see more data but aren't ruling out the potential need for booster doses.\nWhy all of this matters\nClearly, Pfizer, BioNTech, and Moderna benefit financially if booster doses are needed. The more COVID-19 vaccine doses are required, the higher the companies' sales will be and the better the vaccine stocks will likely perform.\nGovernment agencies aren't (or at least shouldn't be) concerned with how much money any of these companies make. However, they are responsible for promoting public health. If booster doses are what it takes to effectively fight the spread of COVID-19, they'll be authorized.\nMy hunch is that the recent real-world data from Israel gives a good clue as to what will happen going forward. That data found only 64% efficacy of the Pfizer-BioNTech vaccine against COVID-19 overall, down from 94% a month earlier, primarily because of the spread of the delta variant. If a third booster dose can get efficacy closer to the initial level, it would be shocking if authorizations aren't granted.\nPfizer, Moderna, the CDC, and the FDA might not always be in harmony. However, I predict they'll soon be singing from the same page when it comes to the need for booster doses.","news_type":1},"isVote":1,"tweetType":1,"viewCount":883,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":157097169,"gmtCreate":1625551576251,"gmtModify":1703743544998,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Good sharing....&nbsp;","listText":"Good sharing....&nbsp;","text":"Good sharing....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/157097169","repostId":"1178707952","repostType":4,"isVote":1,"tweetType":1,"viewCount":756,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":155172902,"gmtCreate":1625396017806,"gmtModify":1703741239295,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Wah","listText":"Wah","text":"Wah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/155172902","repostId":"1165340887","repostType":4,"repost":{"id":"1165340887","kind":"news","pubTimestamp":1625257396,"share":"https://ttm.financial/m/news/1165340887?lang=&edition=fundamental","pubTime":"2021-07-03 04:23","market":"us","language":"en","title":"U.S. stocks sweep to fresh highs after strong jobs report","url":"https://stock-news.laohu8.com/highlight/detail?id=1165340887","media":"yahoo","summary":"Stocks rose Friday to record levels as investors digested a key print on the U.S. labor market recovery, which pointed to a faster pace of payroll gains than expected.The S&P 500 set another record high, kicking off the first sessions of the third quarter on a high note. The blue-chip index logged a seventh straight day of gains in its longest winning streak since August 2020. The Nasdaq also hit all-time intraday and closing highs, and the Dow gained to set its first record high since May 7. Sh","content":"<p>Stocks rose Friday to record levels as investors digested a key print on the U.S. labor market recovery, which pointed to a faster pace of payroll gains than expected.</p>\n<p>The S&amp;P 500 set another record high, kicking off the first sessions of the third quarter on a high note. The blue-chip index logged a seventh straight day of gains in its longest winning streak since August 2020. The Nasdaq also hit all-time intraday and closing highs, and the Dow gained to set its first record high since May 7. Shares of Tesla (TSLA) fluctuated before ending slightly higher after the electric car-maker's second-quarter deliveries hit a new record but still missed analysts' estimates, based on Bloomberg consensus data.</p>\n<p>Investorsconsidered the U.S. Labor Department's June jobs report, the central economic data point that came out this week. The print showed a stronger-than-anticipated acceleration in hiring, with non-farm payrolls rising by 850,000 for a sixth straight monthly gain. The unemployment rate, however, unexpectedly ticked up slightly to 5.9%.</p>\n<p>\"This is the 'Goldilocks report' that the market was looking for today. You had a nice print here of 850,000 jobs being added, wage pressure remaining — I wouldn't call them necessarily contained — but surprising here on the downside versus consensus estimates. So this is telling us right now that economic growth is continuing to accelerate here, the jobs market is continuing to heal,\" Emily Roland, co-chief investment strategist at John Hancock Investment Management, told Yahoo Finance. \"We're making progress here in terms of what the Fed has set out to do, which is in order to get unemployment get down, they're going to let inflation run a little bit hot here. Not too hot, not too cold — this is just what the market wants.\"</p>\n<p>Heading into the report, equities have been buoyed by a slew of strong economic data earlier this week, especially on the labor market.Private payrolls rose by a better-than-expected 692,000 in June,according to ADP, andweekly initial jobless claims improved more than expectedto the lowest level since March 2020. Still, other reports underscored the still-prevalent labor supply challenges impacting companies across industries, with the scarcity capping what has otherwise been a robust economic rebound.</p>\n<p>\"It's really the labor market supply that's putting the brake on hiring right now,\" Luke Tilley, chief economist for Wilmington Trust, told Yahoo Finance. \"But we're pretty optimistic, the market is pretty optimistic, and we think that's a big part of what's driving these indexes higher.\"</p>\n<p>Friday's jobs report will also give markets a suggestion as to the timing of the Federal Reserve's next monetary policy move. For now, the Fed has kept in place both of its key crisis-era policies, or quantitative easing and a near-zero benchmark interest rate. However, an especially strong jobs report and faster-than-expected print on wage growth could justify an earlier-than-currently-telegraphed shift by the central bank.</p>\n<p>“For the first time in years, I’m actually worried about a too hot number causing some kind of volatility or pullback in stocks. That’s because the Fed has signaled they are looking to taper QE,\" Tom Essaye, Sevens Report Research founder,told Yahoo Finance. \"And if we get a really, really strong jobs number and a hot wage number, then markets are going to start to say gee, are they going to taper QE maybe before November, or are they going to taper it more intensely than we thought and in a market that's frankly been very calm and a little bit complacent, that could cause volatility.\"</p>\n<p>Still, the Fed has suggested it would not react rashly to single reports, and has given itself leeway to adjust the timeline of its monetary policy pivots as more data comes in.</p>\n<p>\"I think everyone's counting on the Fed continuing really for the foreseeable future. So I don't see any big changes there coming before 2023,\" Octavio Marenzi, CEO and founder of Opimas,told Yahoo Finance.\"And even then the Fed has hedged its bets very significantly — they've basically said we might in 2023 raise interest rates twice, but then again we might not. So I think the smart money is betting things are going to keep on going, they're going to carry on with a very accommodative monetary policy.\"</p>\n<p>Even with the recent strength for stocks, market strategists say that uncertainty about the future of the Fed’s asset purchases and the upcoming earnings season could keep stocks from making major gains in the near term.</p>\n<p>“The market is still very much concerned about the Fed’s reaction function,” said Max Gokhman, head of asset allocation at Pacific Life Fund Advisors, adding that he thought there was still a lot of slack in the labor market.</p>\n<p>4:01 p.m. ET: Stocks close higher, S&amp;P 500 posts longest winning streak since August 2020</p>\n<p>Here's where markets closed out on Friday:</p>\n<ul>\n <li><p><b>S&amp;P 500 (^GSPC)</b>: +32.51 (+0.75%) to 4,352.45</p></li>\n <li><p><b>Dow (^DJI)</b>: +154.4 (+0.45%) to 34,787.93</p></li>\n <li><p><b>Nasdaq (^IXIC)</b>: +116.95 (+0.81%) to 14,639.33</p></li>\n</ul>","source":"lsy1584348713084","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stocks sweep to fresh highs after strong jobs report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stocks sweep to fresh highs after strong jobs report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-03 04:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/stock-market-news-live-updates-july-2-2021-221546079-221120965.html><strong>yahoo</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks rose Friday to record levels as investors digested a key print on the U.S. labor market recovery, which pointed to a faster pace of payroll gains than expected.\nThe S&P 500 set another record ...</p>\n\n<a href=\"https://finance.yahoo.com/news/stock-market-news-live-updates-july-2-2021-221546079-221120965.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index","SPY":"标普500ETF"},"source_url":"https://finance.yahoo.com/news/stock-market-news-live-updates-july-2-2021-221546079-221120965.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165340887","content_text":"Stocks rose Friday to record levels as investors digested a key print on the U.S. labor market recovery, which pointed to a faster pace of payroll gains than expected.\nThe S&P 500 set another record high, kicking off the first sessions of the third quarter on a high note. The blue-chip index logged a seventh straight day of gains in its longest winning streak since August 2020. The Nasdaq also hit all-time intraday and closing highs, and the Dow gained to set its first record high since May 7. Shares of Tesla (TSLA) fluctuated before ending slightly higher after the electric car-maker's second-quarter deliveries hit a new record but still missed analysts' estimates, based on Bloomberg consensus data.\nInvestorsconsidered the U.S. Labor Department's June jobs report, the central economic data point that came out this week. The print showed a stronger-than-anticipated acceleration in hiring, with non-farm payrolls rising by 850,000 for a sixth straight monthly gain. The unemployment rate, however, unexpectedly ticked up slightly to 5.9%.\n\"This is the 'Goldilocks report' that the market was looking for today. You had a nice print here of 850,000 jobs being added, wage pressure remaining — I wouldn't call them necessarily contained — but surprising here on the downside versus consensus estimates. So this is telling us right now that economic growth is continuing to accelerate here, the jobs market is continuing to heal,\" Emily Roland, co-chief investment strategist at John Hancock Investment Management, told Yahoo Finance. \"We're making progress here in terms of what the Fed has set out to do, which is in order to get unemployment get down, they're going to let inflation run a little bit hot here. Not too hot, not too cold — this is just what the market wants.\"\nHeading into the report, equities have been buoyed by a slew of strong economic data earlier this week, especially on the labor market.Private payrolls rose by a better-than-expected 692,000 in June,according to ADP, andweekly initial jobless claims improved more than expectedto the lowest level since March 2020. Still, other reports underscored the still-prevalent labor supply challenges impacting companies across industries, with the scarcity capping what has otherwise been a robust economic rebound.\n\"It's really the labor market supply that's putting the brake on hiring right now,\" Luke Tilley, chief economist for Wilmington Trust, told Yahoo Finance. \"But we're pretty optimistic, the market is pretty optimistic, and we think that's a big part of what's driving these indexes higher.\"\nFriday's jobs report will also give markets a suggestion as to the timing of the Federal Reserve's next monetary policy move. For now, the Fed has kept in place both of its key crisis-era policies, or quantitative easing and a near-zero benchmark interest rate. However, an especially strong jobs report and faster-than-expected print on wage growth could justify an earlier-than-currently-telegraphed shift by the central bank.\n“For the first time in years, I’m actually worried about a too hot number causing some kind of volatility or pullback in stocks. That’s because the Fed has signaled they are looking to taper QE,\" Tom Essaye, Sevens Report Research founder,told Yahoo Finance. \"And if we get a really, really strong jobs number and a hot wage number, then markets are going to start to say gee, are they going to taper QE maybe before November, or are they going to taper it more intensely than we thought and in a market that's frankly been very calm and a little bit complacent, that could cause volatility.\"\nStill, the Fed has suggested it would not react rashly to single reports, and has given itself leeway to adjust the timeline of its monetary policy pivots as more data comes in.\n\"I think everyone's counting on the Fed continuing really for the foreseeable future. So I don't see any big changes there coming before 2023,\" Octavio Marenzi, CEO and founder of Opimas,told Yahoo Finance.\"And even then the Fed has hedged its bets very significantly — they've basically said we might in 2023 raise interest rates twice, but then again we might not. So I think the smart money is betting things are going to keep on going, they're going to carry on with a very accommodative monetary policy.\"\nEven with the recent strength for stocks, market strategists say that uncertainty about the future of the Fed’s asset purchases and the upcoming earnings season could keep stocks from making major gains in the near term.\n“The market is still very much concerned about the Fed’s reaction function,” said Max Gokhman, head of asset allocation at Pacific Life Fund Advisors, adding that he thought there was still a lot of slack in the labor market.\n4:01 p.m. ET: Stocks close higher, S&P 500 posts longest winning streak since August 2020\nHere's where markets closed out on Friday:\n\nS&P 500 (^GSPC): +32.51 (+0.75%) to 4,352.45\nDow (^DJI): +154.4 (+0.45%) to 34,787.93\nNasdaq (^IXIC): +116.95 (+0.81%) to 14,639.33","news_type":1},"isVote":1,"tweetType":1,"viewCount":227,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158374883,"gmtCreate":1625133135242,"gmtModify":1703736804072,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Good!!&nbsp;","listText":"Good!!&nbsp;","text":"Good!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/158374883","repostId":"1104567937","repostType":4,"isVote":1,"tweetType":1,"viewCount":182,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158374333,"gmtCreate":1625133124822,"gmtModify":1703736803586,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/158374333","repostId":"1104567937","repostType":4,"isVote":1,"tweetType":1,"viewCount":278,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158375788,"gmtCreate":1625133113244,"gmtModify":1703736803261,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/158375788","repostId":"1104567937","repostType":4,"isVote":1,"tweetType":1,"viewCount":140,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158094972,"gmtCreate":1625112027396,"gmtModify":1703736399321,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/158094972","repostId":"1166734232","repostType":4,"repost":{"id":"1166734232","kind":"news","pubTimestamp":1625105837,"share":"https://ttm.financial/m/news/1166734232?lang=&edition=fundamental","pubTime":"2021-07-01 10:17","market":"us","language":"en","title":"CCIV Stock: 5 Reasons Churchill Shares Are Climbing Ahead of a Lucid Motors Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=1166734232","media":"investorplace","summary":"Ahead of the highly anticipated merger with Lucid Motors, investors in Churchill Capital(NYSE:CCIV) ","content":"<p>Ahead of the highly anticipated merger with&nbsp;<b>Lucid Motors</b>, investors in&nbsp;<b>Churchill Capital</b>(NYSE:<b><u>CCIV</u></b>) and CCIV stock have started to see some positive momentum. Indeed, CCIV stock closed higher by nearly 10% on heavy volume today.</p>\n<p>These recent moves come amid a resurgence in the growth stock market. Investors appear to be willing to risk more capital in the markets today than ever before. And amid this risk-on sentiment, SPACs and de-SPAC companies are once again finding momentum.</p>\n<p>That said, Churchill Capital is a company with its own set of catalysts right now. Let’s dive into five of the key factors driving CCIV shares higher today.</p>\n<p>CCIV Stock Higher on Key Catalysts</p>\n<p>Perhaps the key catalyst driving shares of CCIV stock higher today is preorder data. The companyreportedrecently that it has just reached a new milestone with respect to preorders. In fact, the company boasts having 10,000 preorders for its flagship Lucid Air vehicle. These preorders are “bona fide reservations with appropriate deposits.” Indeed, Lucid is being careful to specify this, given the preorder fiascos we’ve seen with other EV players.</p>\n<p>Additionally, in the company’spress release, Lucid’s CEO Peter Rawlinson made some interesting comments. He said the following, of the prospective “two-horse race” between<b>Tesla</b>(NASDAQ:<b><u>TSLA</u></b>) and Lucid, “Ultimately, it’s the technology that’s going to win, and what’s missing here is the recognition that this is a technology race. And right now, there is one runner in that tech race, and it’s Tesla. That’s why Tesla commands that market cap. That’s why it’s in that preeminent position. We have world-class technology, and we aim to make this a two-horse race.”</p>\n<p>On top of this press release,Evercore ISIcame out “impressed” by Lucid’s product line following a test drive of the Grand Touring Edition Air. Indeed, Evercore appears to be more bullish than ever on Lucid’s products, after assessing its product line as well as its preorder increase and its potential commercialization ramp.</p>\n<p>These comments were compounded by a walkthrough of Lucid’s flagship New York Studio, which Evercore noted similar enthusiasm for.</p>\n<p>Finally, the company’s upcomingmerger voteis increasingly being seen as a buy-the-news event. Should shareholders vote as investors expect, Churchill could see additional buying pressure over the near term.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CCIV Stock: 5 Reasons Churchill Shares Are Climbing Ahead of a Lucid Motors Merger</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCCIV Stock: 5 Reasons Churchill Shares Are Climbing Ahead of a Lucid Motors Merger\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-01 10:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/cciv-stock-5-reasons-churchill-shares-are-climbing-ahead-of-a-lucid-motors-merger/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ahead of the highly anticipated merger with Lucid Motors, investors in Churchill Capital(NYSE:CCIV) and CCIV stock have started to see some positive momentum. Indeed, CCIV stock closed higher by ...</p>\n\n<a href=\"https://investorplace.com/2021/06/cciv-stock-5-reasons-churchill-shares-are-climbing-ahead-of-a-lucid-motors-merger/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/cciv-stock-5-reasons-churchill-shares-are-climbing-ahead-of-a-lucid-motors-merger/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166734232","content_text":"Ahead of the highly anticipated merger with Lucid Motors, investors in Churchill Capital(NYSE:CCIV) and CCIV stock have started to see some positive momentum. Indeed, CCIV stock closed higher by nearly 10% on heavy volume today.\nThese recent moves come amid a resurgence in the growth stock market. Investors appear to be willing to risk more capital in the markets today than ever before. And amid this risk-on sentiment, SPACs and de-SPAC companies are once again finding momentum.\nThat said, Churchill Capital is a company with its own set of catalysts right now. Let’s dive into five of the key factors driving CCIV shares higher today.\nCCIV Stock Higher on Key Catalysts\nPerhaps the key catalyst driving shares of CCIV stock higher today is preorder data. The companyreportedrecently that it has just reached a new milestone with respect to preorders. In fact, the company boasts having 10,000 preorders for its flagship Lucid Air vehicle. These preorders are “bona fide reservations with appropriate deposits.” Indeed, Lucid is being careful to specify this, given the preorder fiascos we’ve seen with other EV players.\nAdditionally, in the company’spress release, Lucid’s CEO Peter Rawlinson made some interesting comments. He said the following, of the prospective “two-horse race” betweenTesla(NASDAQ:TSLA) and Lucid, “Ultimately, it’s the technology that’s going to win, and what’s missing here is the recognition that this is a technology race. And right now, there is one runner in that tech race, and it’s Tesla. That’s why Tesla commands that market cap. That’s why it’s in that preeminent position. We have world-class technology, and we aim to make this a two-horse race.”\nOn top of this press release,Evercore ISIcame out “impressed” by Lucid’s product line following a test drive of the Grand Touring Edition Air. Indeed, Evercore appears to be more bullish than ever on Lucid’s products, after assessing its product line as well as its preorder increase and its potential commercialization ramp.\nThese comments were compounded by a walkthrough of Lucid’s flagship New York Studio, which Evercore noted similar enthusiasm for.\nFinally, the company’s upcomingmerger voteis increasingly being seen as a buy-the-news event. Should shareholders vote as investors expect, Churchill could see additional buying pressure over the near term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122244340,"gmtCreate":1624625269480,"gmtModify":1703842013541,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/122244340","repostId":"1105168683","repostType":4,"isVote":1,"tweetType":1,"viewCount":256,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167124506,"gmtCreate":1624253607505,"gmtModify":1703831674912,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":8,"repostSize":0,"link":"https://ttm.financial/post/167124506","repostId":"2145083892","repostType":4,"repost":{"id":"2145083892","kind":"news","pubTimestamp":1624251000,"share":"https://ttm.financial/m/news/2145083892?lang=&edition=fundamental","pubTime":"2021-06-21 12:50","market":"sg","language":"en","title":"Huawei quietly powers up chipmaking investments","url":"https://stock-news.laohu8.com/highlight/detail?id=2145083892","media":"The Straits Times","summary":"(CAIXIN GLOBAL) - Embattled telecoms-equipment maker Huawei Technologies has extended a recent move ","content":"<div>\n<p>(CAIXIN GLOBAL) - Embattled telecoms-equipment maker Huawei Technologies has extended a recent move into the high-tech microchip sector with a new investment in high-powered lasers, as it seeks to ...</p>\n\n<a href=\"http://www.straitstimes.com/asia/east-asia/huawei-quietly-powers-up-chipmaking-investments\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Huawei quietly powers up chipmaking investments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHuawei quietly powers up chipmaking investments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-21 12:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/asia/east-asia/huawei-quietly-powers-up-chipmaking-investments><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(CAIXIN GLOBAL) - Embattled telecoms-equipment maker Huawei Technologies has extended a recent move into the high-tech microchip sector with a new investment in high-powered lasers, as it seeks to ...</p>\n\n<a href=\"http://www.straitstimes.com/asia/east-asia/huawei-quietly-powers-up-chipmaking-investments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"http://www.straitstimes.com/asia/east-asia/huawei-quietly-powers-up-chipmaking-investments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145083892","content_text":"(CAIXIN GLOBAL) - Embattled telecoms-equipment maker Huawei Technologies has extended a recent move into the high-tech microchip sector with a new investment in high-powered lasers, as it seeks to lower its dependence on foreign technology.\nIn its latest move into the space, Huawei's fully-owned Hubble Technology Investment Co Ltd on June 2 invested in RSLaser, whose products are used in the lithography process central to making the microchips that power most modern devices.","news_type":1},"isVote":1,"tweetType":1,"viewCount":351,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167124809,"gmtCreate":1624253588601,"gmtModify":1703831674420,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":9,"repostSize":0,"link":"https://ttm.financial/post/167124809","repostId":"2145083892","repostType":4,"repost":{"id":"2145083892","kind":"news","pubTimestamp":1624251000,"share":"https://ttm.financial/m/news/2145083892?lang=&edition=fundamental","pubTime":"2021-06-21 12:50","market":"sg","language":"en","title":"Huawei quietly powers up chipmaking investments","url":"https://stock-news.laohu8.com/highlight/detail?id=2145083892","media":"The Straits Times","summary":"(CAIXIN GLOBAL) - Embattled telecoms-equipment maker Huawei Technologies has extended a recent move ","content":"<div>\n<p>(CAIXIN GLOBAL) - Embattled telecoms-equipment maker Huawei Technologies has extended a recent move into the high-tech microchip sector with a new investment in high-powered lasers, as it seeks to ...</p>\n\n<a href=\"http://www.straitstimes.com/asia/east-asia/huawei-quietly-powers-up-chipmaking-investments\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Huawei quietly powers up chipmaking investments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHuawei quietly powers up chipmaking investments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-21 12:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/asia/east-asia/huawei-quietly-powers-up-chipmaking-investments><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(CAIXIN GLOBAL) - Embattled telecoms-equipment maker Huawei Technologies has extended a recent move into the high-tech microchip sector with a new investment in high-powered lasers, as it seeks to ...</p>\n\n<a href=\"http://www.straitstimes.com/asia/east-asia/huawei-quietly-powers-up-chipmaking-investments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"http://www.straitstimes.com/asia/east-asia/huawei-quietly-powers-up-chipmaking-investments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145083892","content_text":"(CAIXIN GLOBAL) - Embattled telecoms-equipment maker Huawei Technologies has extended a recent move into the high-tech microchip sector with a new investment in high-powered lasers, as it seeks to lower its dependence on foreign technology.\nIn its latest move into the space, Huawei's fully-owned Hubble Technology Investment Co Ltd on June 2 invested in RSLaser, whose products are used in the lithography process central to making the microchips that power most modern devices.","news_type":1},"isVote":1,"tweetType":1,"viewCount":262,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":898580477,"gmtCreate":1628510353099,"gmtModify":1703507281286,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":13,"repostSize":0,"link":"https://ttm.financial/post/898580477","repostId":"2158844506","repostType":4,"repost":{"id":"2158844506","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1628508062,"share":"https://ttm.financial/m/news/2158844506?lang=&edition=fundamental","pubTime":"2021-08-09 19:21","market":"us","language":"en","title":"BioNTech says has supplied more than 1 bln COVID-19 vaccine doses so far","url":"https://stock-news.laohu8.com/highlight/detail?id=2158844506","media":"Reuters","summary":"FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than one billion doses o","content":"<p>FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca , the German biotech group said on Monday.</p>\n<p>AstraZeneca said on July 29 that it and its manufacturing partner, India-based Serum Institute, had supplied a billion doses to 170 countries at the time.</p>\n<p>Based on delivery contracts so far, BioNTech said in a statement it expects 15.9 billion euros ($18.7 billion) in revenue accruing to it from the vaccine this year, up from a forecast in May of 12.4 billion euros.</p>\n<p>That includes sales, milestone payments from partners and a share of gross profit in its partners' territories, the company added. ($1 = 0.8509 euros)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech says has supplied more than 1 bln COVID-19 vaccine doses so far</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech says has supplied more than 1 bln COVID-19 vaccine doses so far\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-09 19:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca , the German biotech group said on Monday.</p>\n<p>AstraZeneca said on July 29 that it and its manufacturing partner, India-based Serum Institute, had supplied a billion doses to 170 countries at the time.</p>\n<p>Based on delivery contracts so far, BioNTech said in a statement it expects 15.9 billion euros ($18.7 billion) in revenue accruing to it from the vaccine this year, up from a forecast in May of 12.4 billion euros.</p>\n<p>That includes sales, milestone payments from partners and a share of gross profit in its partners' territories, the company added. ($1 = 0.8509 euros)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158844506","content_text":"FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than one billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca , the German biotech group said on Monday.\nAstraZeneca said on July 29 that it and its manufacturing partner, India-based Serum Institute, had supplied a billion doses to 170 countries at the time.\nBased on delivery contracts so far, BioNTech said in a statement it expects 15.9 billion euros ($18.7 billion) in revenue accruing to it from the vaccine this year, up from a forecast in May of 12.4 billion euros.\nThat includes sales, milestone payments from partners and a share of gross profit in its partners' territories, the company added. ($1 = 0.8509 euros)","news_type":1},"isVote":1,"tweetType":1,"viewCount":1097,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891760413,"gmtCreate":1628430549032,"gmtModify":1703506167813,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":12,"repostSize":0,"link":"https://ttm.financial/post/891760413","repostId":"2157492839","repostType":4,"repost":{"id":"2157492839","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1628324123,"share":"https://ttm.financial/m/news/2157492839?lang=&edition=fundamental","pubTime":"2021-08-07 16:15","market":"us","language":"en","title":"India approves J&J COVID-19 vaccine for emergency use","url":"https://stock-news.laohu8.com/highlight/detail?id=2157492839","media":"Reuters","summary":"Aug 7 (Reuters) - India approved Johnson & Johnson's single-dose COVID-19 vaccine for emergency use ","content":"<p>Aug 7 (Reuters) - India approved Johnson &amp; Johnson's single-dose COVID-19 vaccine for emergency use on Saturday, health minister Mansukh Mandaviya said in a tweet.</p>\n<p>The pharmaceutical giant had applied for emergency use approval on Friday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>India approves J&J COVID-19 vaccine for emergency use</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIndia approves J&J COVID-19 vaccine for emergency use\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-07 16:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Aug 7 (Reuters) - India approved Johnson &amp; Johnson's single-dose COVID-19 vaccine for emergency use on Saturday, health minister Mansukh Mandaviya said in a tweet.</p>\n<p>The pharmaceutical giant had applied for emergency use approval on Friday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2157492839","content_text":"Aug 7 (Reuters) - India approved Johnson & Johnson's single-dose COVID-19 vaccine for emergency use on Saturday, health minister Mansukh Mandaviya said in a tweet.\nThe pharmaceutical giant had applied for emergency use approval on Friday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1144,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899173312,"gmtCreate":1628171444836,"gmtModify":1703502518229,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":12,"repostSize":0,"link":"https://ttm.financial/post/899173312","repostId":"1123028494","repostType":4,"repost":{"id":"1123028494","kind":"news","pubTimestamp":1628168579,"share":"https://ttm.financial/m/news/1123028494?lang=&edition=fundamental","pubTime":"2021-08-05 21:02","market":"us","language":"en","title":"SPACs Target Emerging Markets as U.S. Competition Mounts","url":"https://stock-news.laohu8.com/highlight/detail?id=1123028494","media":"The Wall Street Journal","summary":"The number of blank-check companies focused on developing countries has almost tripled in 2021 as in","content":"<blockquote>\n The number of blank-check companies focused on developing countries has almost tripled in 2021 as investors look for better value overseas.\n</blockquote>\n<p>Blank-check companies are venturing to far-flung locales such as Brazil, Israel and Turkey to find attractive merger targets these days.</p>\n<p>Special-purpose acquisition companies, or SPACs, explicitly pursuing companies in Asia, Latin America, Eastern Europe, the Middle East and Africa remain a small part of the overall market. But they are growing at a faster clip than their conventional counterparts, according to The Wall Street Journal’s analysis of data from SPAC Research.</p>\n<p>Sixty new SPACs focused on emerging markets filed documents with the Securities and Exchange Commission in the first half of 2021, almost triple the number for all of 2020, according to the analysis. The number of non-emerging-market SPACs grew by about 67% to 515 over the same period.</p>\n<p>The surge coincides with mounting competition that has driven up purchase prices, and a selloff that has buffeted the U.S. SPAC market in recent months.</p>\n<p>SPACs are shell firms that raise money on stock exchanges, then merge with private companies and take them public. With so-manybuyers chasing dealsin the U.S., blank-check companies are more likely to overpay or to purchase speculative businesses because they must close deals within two years of launching or give investors their money back. The bidding wars have grown so heated that Wall Street insiders have taken to calling them SPAC-offs.</p>\n<p>“People are finding two Stanford dropouts with a twinkle in their eye and a plan to colonize Venus and giving them $2 billion,” said Daniel Freifeld, founder of Callaway Capital Management LLC, a money manager focused on emerging markets.</p>\n<p>Callaway completed a $125 million SPAC in July that listed on the New York Stock Exchange and is targeting Turkish financial-technology companies.</p>\n<p>Turkey is a prime example of the risks that foreign investors take playing in developing markets. Political instability, high inflation and erratic monetary policy have sent the country’s stock market andcurrency into a tailspindespite the global economic recovery this year. The Turkey BIST 100 stock index lost 5.2% in 2021 through Aug. 2, making it the third-worst performer of the global benchmark indexes listed by FactSet.</p>\n<p>“Nowhere in the world is cheaper than Turkey right now,” Mr. Freifeld said&nbsp;Still, the country’s banks and insurance companies are well capitalized and its young population is underbanked, creating strong growth prospects for the financial sector, according to Mr. Freifeld, who says Turkish assets are unlikely to fall much further.</p>\n<p>Most SPACs focused on emerging markets list on U.S. stock exchanges, where relatively stringent reporting and regulatory requirements give investors comfort, said Matthew Simpson, managing partner at WealthSpring Capital, which has about $750 million it invests in SPACs. They also give SPAC investors a way to reduce concentration in the U.S., where lofty valuations andwarnings from regulatorshave recently sparkeda sharp selloff.</p>\n<p>“We actually like adding a lot of foreign-focused SPACs in our portfolio because it adds diversity,” Mr. Simpson said.</p>\n<p></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SPACs Target Emerging Markets as U.S. Competition Mounts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSPACs Target Emerging Markets as U.S. Competition Mounts\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 21:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/spacs-target-emerging-markets-as-u-s-competition-mounts-11628161381?mod=markets_lead_pos4><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The number of blank-check companies focused on developing countries has almost tripled in 2021 as investors look for better value overseas.\n\nBlank-check companies are venturing to far-flung locales ...</p>\n\n<a href=\"https://www.wsj.com/articles/spacs-target-emerging-markets-as-u-s-competition-mounts-11628161381?mod=markets_lead_pos4\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.wsj.com/articles/spacs-target-emerging-markets-as-u-s-competition-mounts-11628161381?mod=markets_lead_pos4","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123028494","content_text":"The number of blank-check companies focused on developing countries has almost tripled in 2021 as investors look for better value overseas.\n\nBlank-check companies are venturing to far-flung locales such as Brazil, Israel and Turkey to find attractive merger targets these days.\nSpecial-purpose acquisition companies, or SPACs, explicitly pursuing companies in Asia, Latin America, Eastern Europe, the Middle East and Africa remain a small part of the overall market. But they are growing at a faster clip than their conventional counterparts, according to The Wall Street Journal’s analysis of data from SPAC Research.\nSixty new SPACs focused on emerging markets filed documents with the Securities and Exchange Commission in the first half of 2021, almost triple the number for all of 2020, according to the analysis. The number of non-emerging-market SPACs grew by about 67% to 515 over the same period.\nThe surge coincides with mounting competition that has driven up purchase prices, and a selloff that has buffeted the U.S. SPAC market in recent months.\nSPACs are shell firms that raise money on stock exchanges, then merge with private companies and take them public. With so-manybuyers chasing dealsin the U.S., blank-check companies are more likely to overpay or to purchase speculative businesses because they must close deals within two years of launching or give investors their money back. The bidding wars have grown so heated that Wall Street insiders have taken to calling them SPAC-offs.\n“People are finding two Stanford dropouts with a twinkle in their eye and a plan to colonize Venus and giving them $2 billion,” said Daniel Freifeld, founder of Callaway Capital Management LLC, a money manager focused on emerging markets.\nCallaway completed a $125 million SPAC in July that listed on the New York Stock Exchange and is targeting Turkish financial-technology companies.\nTurkey is a prime example of the risks that foreign investors take playing in developing markets. Political instability, high inflation and erratic monetary policy have sent the country’s stock market andcurrency into a tailspindespite the global economic recovery this year. The Turkey BIST 100 stock index lost 5.2% in 2021 through Aug. 2, making it the third-worst performer of the global benchmark indexes listed by FactSet.\n“Nowhere in the world is cheaper than Turkey right now,” Mr. Freifeld said Still, the country’s banks and insurance companies are well capitalized and its young population is underbanked, creating strong growth prospects for the financial sector, according to Mr. Freifeld, who says Turkish assets are unlikely to fall much further.\nMost SPACs focused on emerging markets list on U.S. stock exchanges, where relatively stringent reporting and regulatory requirements give investors comfort, said Matthew Simpson, managing partner at WealthSpring Capital, which has about $750 million it invests in SPACs. They also give SPAC investors a way to reduce concentration in the U.S., where lofty valuations andwarnings from regulatorshave recently sparkeda sharp selloff.\n“We actually like adding a lot of foreign-focused SPACs in our portfolio because it adds diversity,” Mr. Simpson said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1028,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9098166768,"gmtCreate":1644048091408,"gmtModify":1676533886340,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Tks sharing","listText":"Tks sharing","text":"Tks sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098166768","repostId":"2209341821","repostType":4,"isVote":1,"tweetType":1,"viewCount":659,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802186750,"gmtCreate":1627733831370,"gmtModify":1703495327500,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":10,"repostSize":0,"link":"https://ttm.financial/post/802186750","repostId":"1147779023","repostType":4,"repost":{"id":"1147779023","kind":"news","pubTimestamp":1627716124,"share":"https://ttm.financial/m/news/1147779023?lang=&edition=fundamental","pubTime":"2021-07-31 15:22","market":"us","language":"en","title":"You can beat stock market indexes — this fund manager has, and this is how she and her team did it","url":"https://stock-news.laohu8.com/highlight/detail?id=1147779023","media":"MarketWatch","summary":"Five key lessons on outperformance from Prabha Ram at the American Century Focused Dynamic Growth Fu","content":"<blockquote>\n <b>Five key lessons on outperformance from Prabha Ram at the American Century Focused Dynamic Growth Fund.</b>\n</blockquote>\n<p>Investing is a tough game. That’s why so many mutual funds lag behind their indices.</p>\n<p>So when you find a fund with a great record, it pays to investigate what the fund managers are doing — to learn some lessons.</p>\n<p>The American Century Focused Dynamic Growth FundACFSXfits the bill. The $2.8 billion fund beats its Russell 1000 Growth&nbsp;Index by over 6 percentage points annualized over the past three and five years, according toMorningstar. It outperforms its large-growth category by 8.6 percentage points annualized over five years. It has a reasonable 0.65% expense ratio.</p>\n<p>The fund is co-managed by Prabha Ram, who I recently caught up with. Raised in India, Ram came to the U.S. as a teaching assistant at the University of Maine, where she earned a master’s degree in computer science. She went on to receive an MBA at the Wharton School at the University of Pennsylvania. Ram and three other portfolio managers have led this fund since 2016.</p>\n<p>Here are the five key takeaways, with examples of specific stocks.</p>\n<p><b>1. Own companies that can “land and expand” in big markets</b></p>\n<p>Even though we’ve been in the digital age for years, many small companies still do much of their business on paper. Bill.comBILLwants to change that. The company was founded by CEO René Lacerte, who in the late 1990s started the online payroll company PayCycle, which was acquired by Intuit.</p>\n<p>Bill.com helps small companies go digital in accounts payable and receivable payments. But that’s just the start. Once inside a company, Bill.com digitizes other areas like cash and expense account management.</p>\n<p>Bill.com “lands and expands” at clients, but it also uses their business partners to create a network of leads.</p>\n<p>“Every vendor is a network member, even if it is not a Bill.com customer,” says Ram. This network has about 2.5 million members. Bill.com also gets prospects from its partners, including Bank of AmericaBAC,JPMorgan ChaseJPMand American ExpressAXP.Sales grew 45% in the first quarter.</p>\n<p>Founder-run companies such as this one are worth considering because they often outperform.</p>\n<p><b>2. Seek out innovators</b></p>\n<p>Ram’s portfolio contains obvious innovators, including TeslaTSLA,Amazon.comAMZNand AlphabetGOOGL,her top three positions. Let’s look beyond technology — to beer.</p>\n<p>Back in the 1980s, Boston Beer founder Jim Koch began taking share from beer giants Anheuser-Busch InBevBUDand HeinekenHEINYby rolling out successful “craft” brews, starting with Samuel Adams. Koch helped invent the craft brew category, essentially taking the country back to pre-Prohibition days when the U.S. had hundreds of regional breweries making more flavorful beers for local tastes.</p>\n<p>Boston Beer stock did very well, but then it stalled during 2015-2017 as beer sales overall went flat. In response, Boston Beer helped put a new category on the map — with its Truly Hard Seltzer brand rolled out in 2106. It remains one of the leading hard seltzers.</p>\n<p>“We were drawn to the company because of its history of innovation,” says Ram, referring to her fund’s early position from the second quarter of 2016. “The stock was doing poorly because the beer market was flattening, but they were coming up with Truly Hard Seltzer. Truly was more successful than we anticipated. It created a new category.”</p>\n<p>This penchant for innovation at Boston Beer has helped keep Ram’s fund in the name. Other successful Boston Beer brands include Twisted Tea, Angry Orchard and Dogfish Head.</p>\n<p>A key takeaway here is that to find innovative companies, look for the ones led by people who have demonstrated a knack for innovation in the past. Innovative managers tend to keep on innovating. Boston Beer continually tests new seltzers, beers, hard ciders, distilled spirits and other drinks. Shareholders are betting they will come through again.</p>\n<p>They’ll need the help. Boston Beer shares fell 20% on July 23 because so many competitors entered the hard cider niche. Sales grew 33% but net income fell 1.6% as the company jacked up advertising costs to try to combat the competition. The company slashed estimates for the year on an expected slowdown in sales growth.</p>\n<p>But don’t count out this innovator yet.</p>\n<p>“We recently announced plans to develop new innovative beverages with&nbsp;Beam Suntory&nbsp;that we are planning to launch in early 2022,” Boston Beer’s Koch said. Beam Suntory&nbsp;sells Jim Beam whiskey and other brands of spirits. “We believe these new beverages will further demonstrate our ability to innovate and grow our business as drinker preferences evolve.”</p>\n<p><b>3. Look for companies that can create and dominate a niche</b></p>\n<p>For years as the gig economy emerged, the big credit card companies didn’t really care that much if the local yoga instructor could accept payments with a credit card. SquareSQrecognized this as an opportunity. So it launched its card payment device business in 2009. Since then, it has grown by taking on larger customers, and expanding into new lines of business in financial services such as cash management, debit cards loans and tax filing. Transaction-based revenue grew 27% in the first quarter, and subscription and services revenue soared 88%.</p>\n<p>This is a great example of a company that created a business niche. But it’s also a “land and expand” company because it grows by offering customers new services. Both qualities help companies maintain the competitive advantage Ram likes see in investments.</p>\n<p><b>4. Buy companies in the early stages of rapid growth</b></p>\n<p>One way to find these is to identify companies developing products that will transform an entire industry. Ram thinks that is the case with Alnylam PharmaceuticalsALNY.It’s developing novel therapies base on a technique called RNA interference (RNAi). Inside the body, messenger RNA (mRNA) encodes proteins we need, based on signals from RNA. Sometimes mRNA gets the signals crossed, and it encodes flawed proteins. This causes diseases.</p>\n<p>Alnylam has developed a way to tweak the RNAi pathway to silence the flawed signaling and block the creation of disease-causing proteins. So far, Alnylam has four approved RNAi-based medicines that treat rare hereditary diseases. The company has a dozen other therapies in clinical studies, including six in late-stage development.</p>\n<p>“This is a completely new area of therapeutics,” says Ram. “It is a platform of products that can treat a variety of conditions.”</p>\n<p><b>5. Hold stocks for the long term</b></p>\n<p>All of the names above are large positions in Ram’s fund, which tells me that Ram and her team think they have considerably more upside. If you buy any of them, though, remember you have to do so with a multi-year time horizon. That’s what Ram’s fund does. It has a low annual portfolio turnover of 27%. It’s important to have a long-term view, because it is so tough to call short-term moves in the stock market or in stocks, and you need to give companies time to develop.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>You can beat stock market indexes — this fund manager has, and this is how she and her team did it</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYou can beat stock market indexes — this fund manager has, and this is how she and her team did it\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-31 15:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/you-can-beat-stock-market-indexes-this-fund-manager-has-and-this-is-how-she-and-her-team-did-it-11627481445?mod=article_inline><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Five key lessons on outperformance from Prabha Ram at the American Century Focused Dynamic Growth Fund.\n\nInvesting is a tough game. That’s why so many mutual funds lag behind their indices.\nSo when ...</p>\n\n<a href=\"https://www.marketwatch.com/story/you-can-beat-stock-market-indexes-this-fund-manager-has-and-this-is-how-she-and-her-team-did-it-11627481445?mod=article_inline\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯","SPY":"标普500ETF",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://www.marketwatch.com/story/you-can-beat-stock-market-indexes-this-fund-manager-has-and-this-is-how-she-and-her-team-did-it-11627481445?mod=article_inline","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147779023","content_text":"Five key lessons on outperformance from Prabha Ram at the American Century Focused Dynamic Growth Fund.\n\nInvesting is a tough game. That’s why so many mutual funds lag behind their indices.\nSo when you find a fund with a great record, it pays to investigate what the fund managers are doing — to learn some lessons.\nThe American Century Focused Dynamic Growth FundACFSXfits the bill. The $2.8 billion fund beats its Russell 1000 Growth Index by over 6 percentage points annualized over the past three and five years, according toMorningstar. It outperforms its large-growth category by 8.6 percentage points annualized over five years. It has a reasonable 0.65% expense ratio.\nThe fund is co-managed by Prabha Ram, who I recently caught up with. Raised in India, Ram came to the U.S. as a teaching assistant at the University of Maine, where she earned a master’s degree in computer science. She went on to receive an MBA at the Wharton School at the University of Pennsylvania. Ram and three other portfolio managers have led this fund since 2016.\nHere are the five key takeaways, with examples of specific stocks.\n1. Own companies that can “land and expand” in big markets\nEven though we’ve been in the digital age for years, many small companies still do much of their business on paper. Bill.comBILLwants to change that. The company was founded by CEO René Lacerte, who in the late 1990s started the online payroll company PayCycle, which was acquired by Intuit.\nBill.com helps small companies go digital in accounts payable and receivable payments. But that’s just the start. Once inside a company, Bill.com digitizes other areas like cash and expense account management.\nBill.com “lands and expands” at clients, but it also uses their business partners to create a network of leads.\n“Every vendor is a network member, even if it is not a Bill.com customer,” says Ram. This network has about 2.5 million members. Bill.com also gets prospects from its partners, including Bank of AmericaBAC,JPMorgan ChaseJPMand American ExpressAXP.Sales grew 45% in the first quarter.\nFounder-run companies such as this one are worth considering because they often outperform.\n2. Seek out innovators\nRam’s portfolio contains obvious innovators, including TeslaTSLA,Amazon.comAMZNand AlphabetGOOGL,her top three positions. Let’s look beyond technology — to beer.\nBack in the 1980s, Boston Beer founder Jim Koch began taking share from beer giants Anheuser-Busch InBevBUDand HeinekenHEINYby rolling out successful “craft” brews, starting with Samuel Adams. Koch helped invent the craft brew category, essentially taking the country back to pre-Prohibition days when the U.S. had hundreds of regional breweries making more flavorful beers for local tastes.\nBoston Beer stock did very well, but then it stalled during 2015-2017 as beer sales overall went flat. In response, Boston Beer helped put a new category on the map — with its Truly Hard Seltzer brand rolled out in 2106. It remains one of the leading hard seltzers.\n“We were drawn to the company because of its history of innovation,” says Ram, referring to her fund’s early position from the second quarter of 2016. “The stock was doing poorly because the beer market was flattening, but they were coming up with Truly Hard Seltzer. Truly was more successful than we anticipated. It created a new category.”\nThis penchant for innovation at Boston Beer has helped keep Ram’s fund in the name. Other successful Boston Beer brands include Twisted Tea, Angry Orchard and Dogfish Head.\nA key takeaway here is that to find innovative companies, look for the ones led by people who have demonstrated a knack for innovation in the past. Innovative managers tend to keep on innovating. Boston Beer continually tests new seltzers, beers, hard ciders, distilled spirits and other drinks. Shareholders are betting they will come through again.\nThey’ll need the help. Boston Beer shares fell 20% on July 23 because so many competitors entered the hard cider niche. Sales grew 33% but net income fell 1.6% as the company jacked up advertising costs to try to combat the competition. The company slashed estimates for the year on an expected slowdown in sales growth.\nBut don’t count out this innovator yet.\n“We recently announced plans to develop new innovative beverages with Beam Suntory that we are planning to launch in early 2022,” Boston Beer’s Koch said. Beam Suntory sells Jim Beam whiskey and other brands of spirits. “We believe these new beverages will further demonstrate our ability to innovate and grow our business as drinker preferences evolve.”\n3. Look for companies that can create and dominate a niche\nFor years as the gig economy emerged, the big credit card companies didn’t really care that much if the local yoga instructor could accept payments with a credit card. SquareSQrecognized this as an opportunity. So it launched its card payment device business in 2009. Since then, it has grown by taking on larger customers, and expanding into new lines of business in financial services such as cash management, debit cards loans and tax filing. Transaction-based revenue grew 27% in the first quarter, and subscription and services revenue soared 88%.\nThis is a great example of a company that created a business niche. But it’s also a “land and expand” company because it grows by offering customers new services. Both qualities help companies maintain the competitive advantage Ram likes see in investments.\n4. Buy companies in the early stages of rapid growth\nOne way to find these is to identify companies developing products that will transform an entire industry. Ram thinks that is the case with Alnylam PharmaceuticalsALNY.It’s developing novel therapies base on a technique called RNA interference (RNAi). Inside the body, messenger RNA (mRNA) encodes proteins we need, based on signals from RNA. Sometimes mRNA gets the signals crossed, and it encodes flawed proteins. This causes diseases.\nAlnylam has developed a way to tweak the RNAi pathway to silence the flawed signaling and block the creation of disease-causing proteins. So far, Alnylam has four approved RNAi-based medicines that treat rare hereditary diseases. The company has a dozen other therapies in clinical studies, including six in late-stage development.\n“This is a completely new area of therapeutics,” says Ram. “It is a platform of products that can treat a variety of conditions.”\n5. Hold stocks for the long term\nAll of the names above are large positions in Ram’s fund, which tells me that Ram and her team think they have considerably more upside. If you buy any of them, though, remember you have to do so with a multi-year time horizon. That’s what Ram’s fund does. It has a low annual portfolio turnover of 27%. It’s important to have a long-term view, because it is so tough to call short-term moves in the stock market or in stocks, and you need to give companies time to develop.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1194,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":800544481,"gmtCreate":1627309952343,"gmtModify":1703487389201,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":9,"repostSize":0,"link":"https://ttm.financial/post/800544481","repostId":"1150818931","repostType":4,"repost":{"id":"1150818931","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627309255,"share":"https://ttm.financial/m/news/1150818931?lang=&edition=fundamental","pubTime":"2021-07-26 22:20","market":"us","language":"en","title":"EV stocks surged in Monday morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1150818931","media":"Tiger Newspress","summary":"EV stocks surged in Monday morning trading.Lucid Motors spikes 12%,Xpeng Motors and Li Auto jumped 4","content":"<p>EV stocks surged in Monday morning trading.Lucid Motors spikes&nbsp;12%,Xpeng Motors and Li Auto&nbsp;jumped&nbsp;4%,Tesla&nbsp;and&nbsp;Nio&nbsp;rose&nbsp;2%.</p>\n<p><img src=\"https://static.tigerbbs.com/68b40eae8375c009ccfbb5d7183d05ce\" tg-width=\"354\" tg-height=\"476\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks surged in Monday morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks surged in Monday morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-26 22:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EV stocks surged in Monday morning trading.Lucid Motors spikes&nbsp;12%,Xpeng Motors and Li Auto&nbsp;jumped&nbsp;4%,Tesla&nbsp;and&nbsp;Nio&nbsp;rose&nbsp;2%.</p>\n<p><img src=\"https://static.tigerbbs.com/68b40eae8375c009ccfbb5d7183d05ce\" tg-width=\"354\" tg-height=\"476\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车","FSR":"菲斯克","NIO":"蔚来","LI":"理想汽车","NKLA":"Nikola Corporation","LCID":"Lucid Group Inc","TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150818931","content_text":"EV stocks surged in Monday morning trading.Lucid Motors spikes 12%,Xpeng Motors and Li Auto jumped 4%,Tesla and Nio rose 2%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":843,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9068159878,"gmtCreate":1651739869494,"gmtModify":1676534959677,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Tks sharing","listText":"Tks sharing","text":"Tks sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9068159878","repostId":"2233950862","repostType":4,"repost":{"id":"2233950862","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1651739300,"share":"https://ttm.financial/m/news/2233950862?lang=&edition=fundamental","pubTime":"2022-05-05 16:28","market":"us","language":"en","title":"PureTech Health to Buy Back Up to $50 Mln in Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2233950862","media":"Dow Jones","summary":"PureTech Health PLC said Thursday that it will launch a share-buyback program of up to $50 million, ","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/PRTC\">PureTech Health PLC</a> said Thursday that it will launch a share-buyback program of up to $50 million, or 28.6 million ordinary shares.</p><p>The clinical-stage biotechnology company said it is confident that it can return the capital to shareholders while continuing to develop and expand its pipeline and strategic investments.</p><p>The company said the buyback program will be executed via open market purchases.</p><p>PureTech had $413.2 million of consolidated cash and cash equivalents as of March 31, it said.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PureTech Health to Buy Back Up to $50 Mln in Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPureTech Health to Buy Back Up to $50 Mln in Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-05-05 16:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/PRTC\">PureTech Health PLC</a> said Thursday that it will launch a share-buyback program of up to $50 million, or 28.6 million ordinary shares.</p><p>The clinical-stage biotechnology company said it is confident that it can return the capital to shareholders while continuing to develop and expand its pipeline and strategic investments.</p><p>The company said the buyback program will be executed via open market purchases.</p><p>PureTech had $413.2 million of consolidated cash and cash equivalents as of March 31, it said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PRTC":"PureTech Health PLC"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2233950862","content_text":"PureTech Health PLC said Thursday that it will launch a share-buyback program of up to $50 million, or 28.6 million ordinary shares.The clinical-stage biotechnology company said it is confident that it can return the capital to shareholders while continuing to develop and expand its pipeline and strategic investments.The company said the buyback program will be executed via open market purchases.PureTech had $413.2 million of consolidated cash and cash equivalents as of March 31, it said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":418,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":800544900,"gmtCreate":1627309934300,"gmtModify":1703487388053,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":9,"repostSize":0,"link":"https://ttm.financial/post/800544900","repostId":"1150818931","repostType":4,"repost":{"id":"1150818931","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627309255,"share":"https://ttm.financial/m/news/1150818931?lang=&edition=fundamental","pubTime":"2021-07-26 22:20","market":"us","language":"en","title":"EV stocks surged in Monday morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1150818931","media":"Tiger Newspress","summary":"EV stocks surged in Monday morning trading.Lucid Motors spikes 12%,Xpeng Motors and Li Auto jumped 4","content":"<p>EV stocks surged in Monday morning trading.Lucid Motors spikes&nbsp;12%,Xpeng Motors and Li Auto&nbsp;jumped&nbsp;4%,Tesla&nbsp;and&nbsp;Nio&nbsp;rose&nbsp;2%.</p>\n<p><img src=\"https://static.tigerbbs.com/68b40eae8375c009ccfbb5d7183d05ce\" tg-width=\"354\" tg-height=\"476\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks surged in Monday morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks surged in Monday morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-26 22:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EV stocks surged in Monday morning trading.Lucid Motors spikes&nbsp;12%,Xpeng Motors and Li Auto&nbsp;jumped&nbsp;4%,Tesla&nbsp;and&nbsp;Nio&nbsp;rose&nbsp;2%.</p>\n<p><img src=\"https://static.tigerbbs.com/68b40eae8375c009ccfbb5d7183d05ce\" tg-width=\"354\" tg-height=\"476\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车","FSR":"菲斯克","NIO":"蔚来","LI":"理想汽车","NKLA":"Nikola Corporation","LCID":"Lucid Group Inc","TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150818931","content_text":"EV stocks surged in Monday morning trading.Lucid Motors spikes 12%,Xpeng Motors and Li Auto jumped 4%,Tesla and Nio rose 2%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1062,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":336586275557384,"gmtCreate":1723210545798,"gmtModify":1723370388983,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/STI.SI\">$Straits Times Index(STI.SI)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/STI.SI\">$Straits Times Index(STI.SI)$&nbsp;</a>&nbsp;","text":"$Straits Times Index(STI.SI)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/336586275557384","isVote":1,"tweetType":1,"viewCount":233,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167124809,"gmtCreate":1624253588601,"gmtModify":1703831674420,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":9,"repostSize":0,"link":"https://ttm.financial/post/167124809","repostId":"2145083892","repostType":4,"repost":{"id":"2145083892","kind":"news","pubTimestamp":1624251000,"share":"https://ttm.financial/m/news/2145083892?lang=&edition=fundamental","pubTime":"2021-06-21 12:50","market":"sg","language":"en","title":"Huawei quietly powers up chipmaking investments","url":"https://stock-news.laohu8.com/highlight/detail?id=2145083892","media":"The Straits Times","summary":"(CAIXIN GLOBAL) - Embattled telecoms-equipment maker Huawei Technologies has extended a recent move ","content":"<div>\n<p>(CAIXIN GLOBAL) - Embattled telecoms-equipment maker Huawei Technologies has extended a recent move into the high-tech microchip sector with a new investment in high-powered lasers, as it seeks to ...</p>\n\n<a href=\"http://www.straitstimes.com/asia/east-asia/huawei-quietly-powers-up-chipmaking-investments\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Huawei quietly powers up chipmaking investments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHuawei quietly powers up chipmaking investments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-21 12:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/asia/east-asia/huawei-quietly-powers-up-chipmaking-investments><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(CAIXIN GLOBAL) - Embattled telecoms-equipment maker Huawei Technologies has extended a recent move into the high-tech microchip sector with a new investment in high-powered lasers, as it seeks to ...</p>\n\n<a href=\"http://www.straitstimes.com/asia/east-asia/huawei-quietly-powers-up-chipmaking-investments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"http://www.straitstimes.com/asia/east-asia/huawei-quietly-powers-up-chipmaking-investments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145083892","content_text":"(CAIXIN GLOBAL) - Embattled telecoms-equipment maker Huawei Technologies has extended a recent move into the high-tech microchip sector with a new investment in high-powered lasers, as it seeks to lower its dependence on foreign technology.\nIn its latest move into the space, Huawei's fully-owned Hubble Technology Investment Co Ltd on June 2 invested in RSLaser, whose products are used in the lithography process central to making the microchips that power most modern devices.","news_type":1},"isVote":1,"tweetType":1,"viewCount":262,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167124506,"gmtCreate":1624253607505,"gmtModify":1703831674912,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":8,"repostSize":0,"link":"https://ttm.financial/post/167124506","repostId":"2145083892","repostType":4,"repost":{"id":"2145083892","kind":"news","pubTimestamp":1624251000,"share":"https://ttm.financial/m/news/2145083892?lang=&edition=fundamental","pubTime":"2021-06-21 12:50","market":"sg","language":"en","title":"Huawei quietly powers up chipmaking investments","url":"https://stock-news.laohu8.com/highlight/detail?id=2145083892","media":"The Straits Times","summary":"(CAIXIN GLOBAL) - Embattled telecoms-equipment maker Huawei Technologies has extended a recent move ","content":"<div>\n<p>(CAIXIN GLOBAL) - Embattled telecoms-equipment maker Huawei Technologies has extended a recent move into the high-tech microchip sector with a new investment in high-powered lasers, as it seeks to ...</p>\n\n<a href=\"http://www.straitstimes.com/asia/east-asia/huawei-quietly-powers-up-chipmaking-investments\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Huawei quietly powers up chipmaking investments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHuawei quietly powers up chipmaking investments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-21 12:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/asia/east-asia/huawei-quietly-powers-up-chipmaking-investments><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(CAIXIN GLOBAL) - Embattled telecoms-equipment maker Huawei Technologies has extended a recent move into the high-tech microchip sector with a new investment in high-powered lasers, as it seeks to ...</p>\n\n<a href=\"http://www.straitstimes.com/asia/east-asia/huawei-quietly-powers-up-chipmaking-investments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"http://www.straitstimes.com/asia/east-asia/huawei-quietly-powers-up-chipmaking-investments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145083892","content_text":"(CAIXIN GLOBAL) - Embattled telecoms-equipment maker Huawei Technologies has extended a recent move into the high-tech microchip sector with a new investment in high-powered lasers, as it seeks to lower its dependence on foreign technology.\nIn its latest move into the space, Huawei's fully-owned Hubble Technology Investment Co Ltd on June 2 invested in RSLaser, whose products are used in the lithography process central to making the microchips that power most modern devices.","news_type":1},"isVote":1,"tweetType":1,"viewCount":351,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":145454267,"gmtCreate":1626240569059,"gmtModify":1703756163447,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Thanks for sharing&nbsp;","listText":"Thanks for sharing&nbsp;","text":"Thanks for sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/145454267","repostId":"2151550481","repostType":4,"repost":{"id":"2151550481","kind":"highlight","pubTimestamp":1626231600,"share":"https://ttm.financial/m/news/2151550481?lang=&edition=fundamental","pubTime":"2021-07-14 11:00","market":"us","language":"en","title":"Why the CDC and FDA Just Slapped Down Pfizer and Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2151550481","media":"Motley Fool","summary":"There's a bit of a brouhaha over booster doses.","content":"<p><b>Pfizer</b> (NYSE:PFE)&nbsp;and&nbsp;<b>Moderna</b> (NASDAQ:MRNA) have enjoyed good working relationships with both the Centers for Disease Control &amp; Prevention (CDC) and the U.S. Food and Drug Administration (FDA). The FDA granted quick approvals to both drugmakers' COVID-19 vaccines last December. The CDC has encouraged Americans to receive both vaccines.</p>\n<p>However, some might now think that the honeymoon is over. Pfizer and Moderna have recently expressed support for booster doses. The CDC and FDA issued a joint public statement last week that appeared to contradict this view. Here's why the two federal agencies just slapped down Pfizer and Moderna.</p>\n<p><img src=\"https://static.tigerbbs.com/9282ceea65d6d87d5e9d88017233aa2a\" tg-width=\"700\" tg-height=\"408\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>A quick and forceful response</h3>\n<p>On July 8, Pfizer chief scientific officer Mikael Dolsten told Reuters in an interview that his company and its partner, <b>BioNTech</b> (NASDAQ:BNTX), plan to soon file for U.S. and European emergency use authorizations (EUA) for a third booster dose. In a separate interview on the same day with CTV News Channel, Moderna co-founder Derrick Rossi said that \"a booster is almost certainly the way.\"</p>\n<p>Rossi doesn't serve on Moderna's management team or board of directors,&nbsp;so his comments didn't represent the biotech's official stance. However, Moderna CEO Stephane Bancel stated in the company's first-quarter conference call: \"We have said for right now that we believe booster shots will be needed as we believe that the virus is not going away.\"</p>\n<p>Later in the day on July 8, the CDC and FDA issued a joint statement on vaccine boosters. The agencies stated:</p>\n<blockquote>\n Americans who have been fully vaccinated do not need a booster shot at this time. FDA, CDC, and NIH are engaged in a science-based, rigorous process to consider whether or when a booster might be necessary. This process takes into account laboratory data, clinical trial data, and cohort data -- which can include data from specific pharmaceutical companies, but does not rely on those data exclusively. We continue to review any new data as it becomes available and will keep the public informed. We are prepared for booster doses if and when the science demonstrates that they are needed.\n</blockquote>\n<p>The CDC-FDA statement appeared to be a direct slap-down -- especially to Pfizer. But why would the agencies respond so quickly and forcefully? The main reason is probably that they don't want to worry Americans who have already been vaccinated, nor give any reason for unvaccinated individuals to delay receiving a vaccine.</p>\n<p>However, I suspect that the FDA, in particular, also had another motivation. The agency doesn't want to be viewed as having too cozy of a relationship with any drugmaker. It has been heavily criticized for the process followed in approving <b>Biogen</b>'s Alzheimer's disease drug Aduhelm. FDA Commissioner Dr. Janet Woodcock even requested an independent investigation into interactions between the agency's staff and Biogen during the review process for the drug.</p>\n<h3>Reconciliable differences</h3>\n<p>Despite the seeming squabble, I don't think that the CDC and the FDA are really in direct opposition to what Pfizer and Moderna have said. There are several similarities between their public statements.</p>\n<p>Both sides agree that the currently available messenger RNA (mRNA) vaccines remain effective at preventing COVID-19. Both also look to data to form their views.</p>\n<p>Pfizer and BioNTech stated last week that their initial data indicates that a third booster dose generates significantly higher antibody levels than only two doses -- five to 10 times more. The CDC and FDA haven't seen this data yet, though. Pfizer and BioNTech expect to submit the data to the FDA as well as to the European Medicines Agency and other regulatory authorities within the next few weeks.</p>\n<p>The differences between the CDC-FDA view and Pfizer-BioNTech-Moderna perspective appear to be mainly related to timing. The drugmakers believe they've seen enough data to know now that booster doses will be needed, while the federal agencies think they need to see more data but aren't ruling out the potential need for booster doses.</p>\n<h3>Why all of this matters</h3>\n<p>Clearly, Pfizer, BioNTech, and Moderna benefit financially if booster doses are needed. The more COVID-19 vaccine doses are required, the higher the companies' sales will be and the better the vaccine stocks will likely perform.</p>\n<p>Government agencies aren't (or at least shouldn't be) concerned with how much money any of these companies make. However, they are responsible for promoting public health. If booster doses are what it takes to effectively fight the spread of COVID-19, they'll be authorized.</p>\n<p>My hunch is that the recent real-world data from Israel gives a good clue as to what will happen going forward. That data found only 64% efficacy of the Pfizer-BioNTech vaccine against COVID-19 overall, down from 94% a month earlier, primarily because of the spread of the delta variant. If a third booster dose can get efficacy closer to the initial level, it would be shocking if authorizations aren't granted.</p>\n<p>Pfizer, Moderna, the CDC, and the FDA might not always be in harmony. However, I predict they'll soon be singing from the same page when it comes to the need for booster doses.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why the CDC and FDA Just Slapped Down Pfizer and Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy the CDC and FDA Just Slapped Down Pfizer and Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-14 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/13/why-the-fda-and-cdc-just-slapped-down-pfizer-and-m/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) have enjoyed good working relationships with both the Centers for Disease Control & Prevention (CDC) and the U.S. Food and Drug Administration (FDA). The ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/13/why-the-fda-and-cdc-just-slapped-down-pfizer-and-m/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/07/13/why-the-fda-and-cdc-just-slapped-down-pfizer-and-m/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2151550481","content_text":"Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) have enjoyed good working relationships with both the Centers for Disease Control & Prevention (CDC) and the U.S. Food and Drug Administration (FDA). The FDA granted quick approvals to both drugmakers' COVID-19 vaccines last December. The CDC has encouraged Americans to receive both vaccines.\nHowever, some might now think that the honeymoon is over. Pfizer and Moderna have recently expressed support for booster doses. The CDC and FDA issued a joint public statement last week that appeared to contradict this view. Here's why the two federal agencies just slapped down Pfizer and Moderna.\n\nImage source: Getty Images.\nA quick and forceful response\nOn July 8, Pfizer chief scientific officer Mikael Dolsten told Reuters in an interview that his company and its partner, BioNTech (NASDAQ:BNTX), plan to soon file for U.S. and European emergency use authorizations (EUA) for a third booster dose. In a separate interview on the same day with CTV News Channel, Moderna co-founder Derrick Rossi said that \"a booster is almost certainly the way.\"\nRossi doesn't serve on Moderna's management team or board of directors, so his comments didn't represent the biotech's official stance. However, Moderna CEO Stephane Bancel stated in the company's first-quarter conference call: \"We have said for right now that we believe booster shots will be needed as we believe that the virus is not going away.\"\nLater in the day on July 8, the CDC and FDA issued a joint statement on vaccine boosters. The agencies stated:\n\n Americans who have been fully vaccinated do not need a booster shot at this time. FDA, CDC, and NIH are engaged in a science-based, rigorous process to consider whether or when a booster might be necessary. This process takes into account laboratory data, clinical trial data, and cohort data -- which can include data from specific pharmaceutical companies, but does not rely on those data exclusively. We continue to review any new data as it becomes available and will keep the public informed. We are prepared for booster doses if and when the science demonstrates that they are needed.\n\nThe CDC-FDA statement appeared to be a direct slap-down -- especially to Pfizer. But why would the agencies respond so quickly and forcefully? The main reason is probably that they don't want to worry Americans who have already been vaccinated, nor give any reason for unvaccinated individuals to delay receiving a vaccine.\nHowever, I suspect that the FDA, in particular, also had another motivation. The agency doesn't want to be viewed as having too cozy of a relationship with any drugmaker. It has been heavily criticized for the process followed in approving Biogen's Alzheimer's disease drug Aduhelm. FDA Commissioner Dr. Janet Woodcock even requested an independent investigation into interactions between the agency's staff and Biogen during the review process for the drug.\nReconciliable differences\nDespite the seeming squabble, I don't think that the CDC and the FDA are really in direct opposition to what Pfizer and Moderna have said. There are several similarities between their public statements.\nBoth sides agree that the currently available messenger RNA (mRNA) vaccines remain effective at preventing COVID-19. Both also look to data to form their views.\nPfizer and BioNTech stated last week that their initial data indicates that a third booster dose generates significantly higher antibody levels than only two doses -- five to 10 times more. The CDC and FDA haven't seen this data yet, though. Pfizer and BioNTech expect to submit the data to the FDA as well as to the European Medicines Agency and other regulatory authorities within the next few weeks.\nThe differences between the CDC-FDA view and Pfizer-BioNTech-Moderna perspective appear to be mainly related to timing. The drugmakers believe they've seen enough data to know now that booster doses will be needed, while the federal agencies think they need to see more data but aren't ruling out the potential need for booster doses.\nWhy all of this matters\nClearly, Pfizer, BioNTech, and Moderna benefit financially if booster doses are needed. The more COVID-19 vaccine doses are required, the higher the companies' sales will be and the better the vaccine stocks will likely perform.\nGovernment agencies aren't (or at least shouldn't be) concerned with how much money any of these companies make. However, they are responsible for promoting public health. If booster doses are what it takes to effectively fight the spread of COVID-19, they'll be authorized.\nMy hunch is that the recent real-world data from Israel gives a good clue as to what will happen going forward. That data found only 64% efficacy of the Pfizer-BioNTech vaccine against COVID-19 overall, down from 94% a month earlier, primarily because of the spread of the delta variant. If a third booster dose can get efficacy closer to the initial level, it would be shocking if authorizations aren't granted.\nPfizer, Moderna, the CDC, and the FDA might not always be in harmony. However, I predict they'll soon be singing from the same page when it comes to the need for booster doses.","news_type":1},"isVote":1,"tweetType":1,"viewCount":883,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":157097169,"gmtCreate":1625551576251,"gmtModify":1703743544998,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Good sharing....&nbsp;","listText":"Good sharing....&nbsp;","text":"Good sharing....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/157097169","repostId":"1178707952","repostType":4,"isVote":1,"tweetType":1,"viewCount":756,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":155172902,"gmtCreate":1625396017806,"gmtModify":1703741239295,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Wah","listText":"Wah","text":"Wah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/155172902","repostId":"1165340887","repostType":4,"repost":{"id":"1165340887","kind":"news","pubTimestamp":1625257396,"share":"https://ttm.financial/m/news/1165340887?lang=&edition=fundamental","pubTime":"2021-07-03 04:23","market":"us","language":"en","title":"U.S. stocks sweep to fresh highs after strong jobs report","url":"https://stock-news.laohu8.com/highlight/detail?id=1165340887","media":"yahoo","summary":"Stocks rose Friday to record levels as investors digested a key print on the U.S. labor market recovery, which pointed to a faster pace of payroll gains than expected.The S&P 500 set another record high, kicking off the first sessions of the third quarter on a high note. The blue-chip index logged a seventh straight day of gains in its longest winning streak since August 2020. The Nasdaq also hit all-time intraday and closing highs, and the Dow gained to set its first record high since May 7. Sh","content":"<p>Stocks rose Friday to record levels as investors digested a key print on the U.S. labor market recovery, which pointed to a faster pace of payroll gains than expected.</p>\n<p>The S&amp;P 500 set another record high, kicking off the first sessions of the third quarter on a high note. The blue-chip index logged a seventh straight day of gains in its longest winning streak since August 2020. The Nasdaq also hit all-time intraday and closing highs, and the Dow gained to set its first record high since May 7. Shares of Tesla (TSLA) fluctuated before ending slightly higher after the electric car-maker's second-quarter deliveries hit a new record but still missed analysts' estimates, based on Bloomberg consensus data.</p>\n<p>Investorsconsidered the U.S. Labor Department's June jobs report, the central economic data point that came out this week. The print showed a stronger-than-anticipated acceleration in hiring, with non-farm payrolls rising by 850,000 for a sixth straight monthly gain. The unemployment rate, however, unexpectedly ticked up slightly to 5.9%.</p>\n<p>\"This is the 'Goldilocks report' that the market was looking for today. You had a nice print here of 850,000 jobs being added, wage pressure remaining — I wouldn't call them necessarily contained — but surprising here on the downside versus consensus estimates. So this is telling us right now that economic growth is continuing to accelerate here, the jobs market is continuing to heal,\" Emily Roland, co-chief investment strategist at John Hancock Investment Management, told Yahoo Finance. \"We're making progress here in terms of what the Fed has set out to do, which is in order to get unemployment get down, they're going to let inflation run a little bit hot here. Not too hot, not too cold — this is just what the market wants.\"</p>\n<p>Heading into the report, equities have been buoyed by a slew of strong economic data earlier this week, especially on the labor market.Private payrolls rose by a better-than-expected 692,000 in June,according to ADP, andweekly initial jobless claims improved more than expectedto the lowest level since March 2020. Still, other reports underscored the still-prevalent labor supply challenges impacting companies across industries, with the scarcity capping what has otherwise been a robust economic rebound.</p>\n<p>\"It's really the labor market supply that's putting the brake on hiring right now,\" Luke Tilley, chief economist for Wilmington Trust, told Yahoo Finance. \"But we're pretty optimistic, the market is pretty optimistic, and we think that's a big part of what's driving these indexes higher.\"</p>\n<p>Friday's jobs report will also give markets a suggestion as to the timing of the Federal Reserve's next monetary policy move. For now, the Fed has kept in place both of its key crisis-era policies, or quantitative easing and a near-zero benchmark interest rate. However, an especially strong jobs report and faster-than-expected print on wage growth could justify an earlier-than-currently-telegraphed shift by the central bank.</p>\n<p>“For the first time in years, I’m actually worried about a too hot number causing some kind of volatility or pullback in stocks. That’s because the Fed has signaled they are looking to taper QE,\" Tom Essaye, Sevens Report Research founder,told Yahoo Finance. \"And if we get a really, really strong jobs number and a hot wage number, then markets are going to start to say gee, are they going to taper QE maybe before November, or are they going to taper it more intensely than we thought and in a market that's frankly been very calm and a little bit complacent, that could cause volatility.\"</p>\n<p>Still, the Fed has suggested it would not react rashly to single reports, and has given itself leeway to adjust the timeline of its monetary policy pivots as more data comes in.</p>\n<p>\"I think everyone's counting on the Fed continuing really for the foreseeable future. So I don't see any big changes there coming before 2023,\" Octavio Marenzi, CEO and founder of Opimas,told Yahoo Finance.\"And even then the Fed has hedged its bets very significantly — they've basically said we might in 2023 raise interest rates twice, but then again we might not. So I think the smart money is betting things are going to keep on going, they're going to carry on with a very accommodative monetary policy.\"</p>\n<p>Even with the recent strength for stocks, market strategists say that uncertainty about the future of the Fed’s asset purchases and the upcoming earnings season could keep stocks from making major gains in the near term.</p>\n<p>“The market is still very much concerned about the Fed’s reaction function,” said Max Gokhman, head of asset allocation at Pacific Life Fund Advisors, adding that he thought there was still a lot of slack in the labor market.</p>\n<p>4:01 p.m. ET: Stocks close higher, S&amp;P 500 posts longest winning streak since August 2020</p>\n<p>Here's where markets closed out on Friday:</p>\n<ul>\n <li><p><b>S&amp;P 500 (^GSPC)</b>: +32.51 (+0.75%) to 4,352.45</p></li>\n <li><p><b>Dow (^DJI)</b>: +154.4 (+0.45%) to 34,787.93</p></li>\n <li><p><b>Nasdaq (^IXIC)</b>: +116.95 (+0.81%) to 14,639.33</p></li>\n</ul>","source":"lsy1584348713084","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stocks sweep to fresh highs after strong jobs report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stocks sweep to fresh highs after strong jobs report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-03 04:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/stock-market-news-live-updates-july-2-2021-221546079-221120965.html><strong>yahoo</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks rose Friday to record levels as investors digested a key print on the U.S. labor market recovery, which pointed to a faster pace of payroll gains than expected.\nThe S&P 500 set another record ...</p>\n\n<a href=\"https://finance.yahoo.com/news/stock-market-news-live-updates-july-2-2021-221546079-221120965.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index","SPY":"标普500ETF"},"source_url":"https://finance.yahoo.com/news/stock-market-news-live-updates-july-2-2021-221546079-221120965.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165340887","content_text":"Stocks rose Friday to record levels as investors digested a key print on the U.S. labor market recovery, which pointed to a faster pace of payroll gains than expected.\nThe S&P 500 set another record high, kicking off the first sessions of the third quarter on a high note. The blue-chip index logged a seventh straight day of gains in its longest winning streak since August 2020. The Nasdaq also hit all-time intraday and closing highs, and the Dow gained to set its first record high since May 7. Shares of Tesla (TSLA) fluctuated before ending slightly higher after the electric car-maker's second-quarter deliveries hit a new record but still missed analysts' estimates, based on Bloomberg consensus data.\nInvestorsconsidered the U.S. Labor Department's June jobs report, the central economic data point that came out this week. The print showed a stronger-than-anticipated acceleration in hiring, with non-farm payrolls rising by 850,000 for a sixth straight monthly gain. The unemployment rate, however, unexpectedly ticked up slightly to 5.9%.\n\"This is the 'Goldilocks report' that the market was looking for today. You had a nice print here of 850,000 jobs being added, wage pressure remaining — I wouldn't call them necessarily contained — but surprising here on the downside versus consensus estimates. So this is telling us right now that economic growth is continuing to accelerate here, the jobs market is continuing to heal,\" Emily Roland, co-chief investment strategist at John Hancock Investment Management, told Yahoo Finance. \"We're making progress here in terms of what the Fed has set out to do, which is in order to get unemployment get down, they're going to let inflation run a little bit hot here. Not too hot, not too cold — this is just what the market wants.\"\nHeading into the report, equities have been buoyed by a slew of strong economic data earlier this week, especially on the labor market.Private payrolls rose by a better-than-expected 692,000 in June,according to ADP, andweekly initial jobless claims improved more than expectedto the lowest level since March 2020. Still, other reports underscored the still-prevalent labor supply challenges impacting companies across industries, with the scarcity capping what has otherwise been a robust economic rebound.\n\"It's really the labor market supply that's putting the brake on hiring right now,\" Luke Tilley, chief economist for Wilmington Trust, told Yahoo Finance. \"But we're pretty optimistic, the market is pretty optimistic, and we think that's a big part of what's driving these indexes higher.\"\nFriday's jobs report will also give markets a suggestion as to the timing of the Federal Reserve's next monetary policy move. For now, the Fed has kept in place both of its key crisis-era policies, or quantitative easing and a near-zero benchmark interest rate. However, an especially strong jobs report and faster-than-expected print on wage growth could justify an earlier-than-currently-telegraphed shift by the central bank.\n“For the first time in years, I’m actually worried about a too hot number causing some kind of volatility or pullback in stocks. That’s because the Fed has signaled they are looking to taper QE,\" Tom Essaye, Sevens Report Research founder,told Yahoo Finance. \"And if we get a really, really strong jobs number and a hot wage number, then markets are going to start to say gee, are they going to taper QE maybe before November, or are they going to taper it more intensely than we thought and in a market that's frankly been very calm and a little bit complacent, that could cause volatility.\"\nStill, the Fed has suggested it would not react rashly to single reports, and has given itself leeway to adjust the timeline of its monetary policy pivots as more data comes in.\n\"I think everyone's counting on the Fed continuing really for the foreseeable future. So I don't see any big changes there coming before 2023,\" Octavio Marenzi, CEO and founder of Opimas,told Yahoo Finance.\"And even then the Fed has hedged its bets very significantly — they've basically said we might in 2023 raise interest rates twice, but then again we might not. So I think the smart money is betting things are going to keep on going, they're going to carry on with a very accommodative monetary policy.\"\nEven with the recent strength for stocks, market strategists say that uncertainty about the future of the Fed’s asset purchases and the upcoming earnings season could keep stocks from making major gains in the near term.\n“The market is still very much concerned about the Fed’s reaction function,” said Max Gokhman, head of asset allocation at Pacific Life Fund Advisors, adding that he thought there was still a lot of slack in the labor market.\n4:01 p.m. ET: Stocks close higher, S&P 500 posts longest winning streak since August 2020\nHere's where markets closed out on Friday:\n\nS&P 500 (^GSPC): +32.51 (+0.75%) to 4,352.45\nDow (^DJI): +154.4 (+0.45%) to 34,787.93\nNasdaq (^IXIC): +116.95 (+0.81%) to 14,639.33","news_type":1},"isVote":1,"tweetType":1,"viewCount":227,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158374883,"gmtCreate":1625133135242,"gmtModify":1703736804072,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Good!!&nbsp;","listText":"Good!!&nbsp;","text":"Good!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/158374883","repostId":"1104567937","repostType":4,"isVote":1,"tweetType":1,"viewCount":182,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122244340,"gmtCreate":1624625269480,"gmtModify":1703842013541,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/122244340","repostId":"1105168683","repostType":4,"isVote":1,"tweetType":1,"viewCount":256,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158374333,"gmtCreate":1625133124822,"gmtModify":1703736803586,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/158374333","repostId":"1104567937","repostType":4,"isVote":1,"tweetType":1,"viewCount":278,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158375788,"gmtCreate":1625133113244,"gmtModify":1703736803261,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/158375788","repostId":"1104567937","repostType":4,"isVote":1,"tweetType":1,"viewCount":140,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158094972,"gmtCreate":1625112027396,"gmtModify":1703736399321,"author":{"id":"3581503098068541","authorId":"3581503098068541","name":"meehie","avatar":"https://static.tigerbbs.com/176e11db0a6f5b06ef4983dace13a883","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581503098068541","authorIdStr":"3581503098068541"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/158094972","repostId":"1166734232","repostType":4,"repost":{"id":"1166734232","kind":"news","pubTimestamp":1625105837,"share":"https://ttm.financial/m/news/1166734232?lang=&edition=fundamental","pubTime":"2021-07-01 10:17","market":"us","language":"en","title":"CCIV Stock: 5 Reasons Churchill Shares Are Climbing Ahead of a Lucid Motors Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=1166734232","media":"investorplace","summary":"Ahead of the highly anticipated merger with Lucid Motors, investors in Churchill Capital(NYSE:CCIV) ","content":"<p>Ahead of the highly anticipated merger with&nbsp;<b>Lucid Motors</b>, investors in&nbsp;<b>Churchill Capital</b>(NYSE:<b><u>CCIV</u></b>) and CCIV stock have started to see some positive momentum. Indeed, CCIV stock closed higher by nearly 10% on heavy volume today.</p>\n<p>These recent moves come amid a resurgence in the growth stock market. Investors appear to be willing to risk more capital in the markets today than ever before. And amid this risk-on sentiment, SPACs and de-SPAC companies are once again finding momentum.</p>\n<p>That said, Churchill Capital is a company with its own set of catalysts right now. Let’s dive into five of the key factors driving CCIV shares higher today.</p>\n<p>CCIV Stock Higher on Key Catalysts</p>\n<p>Perhaps the key catalyst driving shares of CCIV stock higher today is preorder data. The companyreportedrecently that it has just reached a new milestone with respect to preorders. In fact, the company boasts having 10,000 preorders for its flagship Lucid Air vehicle. These preorders are “bona fide reservations with appropriate deposits.” Indeed, Lucid is being careful to specify this, given the preorder fiascos we’ve seen with other EV players.</p>\n<p>Additionally, in the company’spress release, Lucid’s CEO Peter Rawlinson made some interesting comments. He said the following, of the prospective “two-horse race” between<b>Tesla</b>(NASDAQ:<b><u>TSLA</u></b>) and Lucid, “Ultimately, it’s the technology that’s going to win, and what’s missing here is the recognition that this is a technology race. And right now, there is one runner in that tech race, and it’s Tesla. That’s why Tesla commands that market cap. That’s why it’s in that preeminent position. We have world-class technology, and we aim to make this a two-horse race.”</p>\n<p>On top of this press release,Evercore ISIcame out “impressed” by Lucid’s product line following a test drive of the Grand Touring Edition Air. Indeed, Evercore appears to be more bullish than ever on Lucid’s products, after assessing its product line as well as its preorder increase and its potential commercialization ramp.</p>\n<p>These comments were compounded by a walkthrough of Lucid’s flagship New York Studio, which Evercore noted similar enthusiasm for.</p>\n<p>Finally, the company’s upcomingmerger voteis increasingly being seen as a buy-the-news event. Should shareholders vote as investors expect, Churchill could see additional buying pressure over the near term.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CCIV Stock: 5 Reasons Churchill Shares Are Climbing Ahead of a Lucid Motors Merger</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCCIV Stock: 5 Reasons Churchill Shares Are Climbing Ahead of a Lucid Motors Merger\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-01 10:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/cciv-stock-5-reasons-churchill-shares-are-climbing-ahead-of-a-lucid-motors-merger/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ahead of the highly anticipated merger with Lucid Motors, investors in Churchill Capital(NYSE:CCIV) and CCIV stock have started to see some positive momentum. Indeed, CCIV stock closed higher by ...</p>\n\n<a href=\"https://investorplace.com/2021/06/cciv-stock-5-reasons-churchill-shares-are-climbing-ahead-of-a-lucid-motors-merger/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/cciv-stock-5-reasons-churchill-shares-are-climbing-ahead-of-a-lucid-motors-merger/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166734232","content_text":"Ahead of the highly anticipated merger with Lucid Motors, investors in Churchill Capital(NYSE:CCIV) and CCIV stock have started to see some positive momentum. Indeed, CCIV stock closed higher by nearly 10% on heavy volume today.\nThese recent moves come amid a resurgence in the growth stock market. Investors appear to be willing to risk more capital in the markets today than ever before. And amid this risk-on sentiment, SPACs and de-SPAC companies are once again finding momentum.\nThat said, Churchill Capital is a company with its own set of catalysts right now. Let’s dive into five of the key factors driving CCIV shares higher today.\nCCIV Stock Higher on Key Catalysts\nPerhaps the key catalyst driving shares of CCIV stock higher today is preorder data. The companyreportedrecently that it has just reached a new milestone with respect to preorders. In fact, the company boasts having 10,000 preorders for its flagship Lucid Air vehicle. These preorders are “bona fide reservations with appropriate deposits.” Indeed, Lucid is being careful to specify this, given the preorder fiascos we’ve seen with other EV players.\nAdditionally, in the company’spress release, Lucid’s CEO Peter Rawlinson made some interesting comments. He said the following, of the prospective “two-horse race” betweenTesla(NASDAQ:TSLA) and Lucid, “Ultimately, it’s the technology that’s going to win, and what’s missing here is the recognition that this is a technology race. And right now, there is one runner in that tech race, and it’s Tesla. That’s why Tesla commands that market cap. That’s why it’s in that preeminent position. We have world-class technology, and we aim to make this a two-horse race.”\nOn top of this press release,Evercore ISIcame out “impressed” by Lucid’s product line following a test drive of the Grand Touring Edition Air. Indeed, Evercore appears to be more bullish than ever on Lucid’s products, after assessing its product line as well as its preorder increase and its potential commercialization ramp.\nThese comments were compounded by a walkthrough of Lucid’s flagship New York Studio, which Evercore noted similar enthusiasm for.\nFinally, the company’s upcomingmerger voteis increasingly being seen as a buy-the-news event. Should shareholders vote as investors expect, Churchill could see additional buying pressure over the near term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}